+Follow
Kallu
To achieve your own goals, start by helping others achieve theirs. Study and steady wins the race.
46
Follow
12
Followers
1
Topic
0
Badge
Posts
Hot
Kallu
12-17
$Tonix Pharmaceuticals(TNXP)$
5$ soon
@Barcode
@TigerGPT
@Tiger_SG
Kallu
12-16
$Tonix Pharmaceuticals(TNXP)$
go go
@TigerGPT
$Tonix Pharmaceuticals(TNXP)$
Kallu
10-30
$Trump Media & Technology(DJT)$
it's glitch.. 60$ is loading.. @
@Barcode
you're strong analysis required here to save me ššš
$Trump Media & Technology(DJT)$
Kallu
10-15
"Enjoying the bloodbath today, and it will continue until the end of the week. Prepared for everything."
$NVIDIA Corp(NVDA)$
$Aspen Aerogels(ASPN)$
$Tiger Brokers(TIGR)$
$NASDAQ 100(NDX)$
$.SPX(.SPX)$
@Barcode
@TigerGPT
Why!!!
Kallu
11-20
$Tonix Pharmaceuticals(TNXP)$
$Tonix Pharmaceuticals(TNXP)$
@Barcode
@TigerGPT
$Tonix Pharmaceuticals(TNXP)$
Kallu
10-14
@Barcode
@TigerGPT
$Red Cat Holdings Inc.(RCAT)$
Join the drone show mate
@Barcode
U.S. Army Special Operations Veteran and Drone Expert Joins Red Catās Board of Advisors
Kallu
09-30
$Tonix Pharmaceuticals(TNXP)$
$Tonix Pharmaceuticals(TNXP)$
Kallu
11-13
$NIO Inc.(NIO)$
im exhausted from all the misleading positive reports, only to see stocks stagnate
@Barcode
@TigerGPT
answer me why
$NIO Inc.(NIO)$
is not performing well.
Is Nio About to Shift Into a Higher Gear?
Kallu
09-18
$Intuitive Machines(LUNR)$
$Intuitive Machines(LUNR)$
just a good start..thanks to the mid-autumn festival
Kallu
10-29
$Intel(INTC)$
$Intel(INTC)$
Kallu
10-21
$Tonix Pharmaceuticals(TNXP)$
$Tonix Pharmaceuticals(TNXP)$
@TigerGPT
Any good news about
$Tonix Pharmaceuticals(TNXP)$
Kallu
10-04
$Spirit Airlines(SAVE)$
$Spirit Airlines(SAVE)$
Kallu
08-26
$NVIDIA Corp(NVDA)$
$NVIDIA Corp(NVDA)$
Kallu
10-07
$CN Energy Group Inc.(CNEY)$
$CN Energy Group Inc.(CNEY)$
goneš¤©š¤©
Kallu
10-03
$Faraday Future Intelligent Electric Inc.(FFIE)$
future EV
Faraday Future Announces Executivesā Common Stock Purchases
Kallu
12-20
$Tonix Pharmaceuticals(TNXP)$
Kallu
11-05
$NVIDIA Corp(NVDA)$
Kallu
10-04
$Blink Charging(BLNK)$
$Blink Charging(BLNK)$
Kallu
12-12
$Taboola Com Ltd(TBLA)$
$Taboola Com Ltd(TBLA)$
still not selling
@Barcode
@TigerGPT
Kallu
11-30
Hoping Santa and
@Barcode
brings a market. My portfolio's still in the red, but I'm counting on a December rebound.
@TigerGPT
@Barcode
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4156648821928502","uuid":"4156648821928502","gmtCreate":1693545706295,"gmtModify":1730966832917,"name":"Kallu","pinyin":"kallu","introduction":"","introductionEn":"","signature":"To achieve your own goals, start by helping others achieve theirs. Study and steady wins the race.","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":12,"headSize":46,"tweetSize":134,"questionSize":0,"limitLevel":999,"accountStatus":1,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.06.27","exceedPercentage":"80.93%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.02","exceedPercentage":"60.71%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.19","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.09.07","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.02","exceedPercentage":"60.24%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":6,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":383445721780288,"gmtCreate":1734646545965,"gmtModify":1734646548495,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4156648821928502","idStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> ","listText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> ","text":"$Tonix Pharmaceuticals(TNXP)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/383445721780288","isVote":1,"tweetType":1,"viewCount":55,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":382603205132640,"gmtCreate":1734443997221,"gmtModify":1734492329425,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4156648821928502","idStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a> 5$ soon <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode </a> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a> <a href=\"https://ttm.financial/U/4106547232749330\">@Tiger_SG </a> ","listText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a> 5$ soon <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode </a> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a> <a href=\"https://ttm.financial/U/4106547232749330\">@Tiger_SG </a> ","text":"$Tonix Pharmaceuticals(TNXP)$ 5$ soon @Barcode @TigerGPT @Tiger_SG","images":[{"img":"https://community-static.tradeup.com/news/80fb0a6db8ee66d377f8a3a2a33ea29e","width":"1068","height":"1112"}],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":103,"commentSize":15,"repostSize":723,"link":"https://ttm.financial/post/382603205132640","isVote":1,"tweetType":1,"viewCount":13698,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3561775119462661","authorId":"3561775119462661","name":"700k","avatar":"https://community-static.tradeup.com/news/5dfeb3d580890f8e0e43382fe44965d5","crmLevel":2,"crmLevelSwitch":1,"authorIdStr":"3561775119462661","idStr":"3561775119462661"},"content":"hope you have sold it when it reach above $1. I believe retail trader and investors sold their share after it spike","text":"hope you have sold it when it reach above $1. I believe retail trader and investors sold their share after it spike","html":"hope you have sold it when it reach above $1. I believe retail trader and investors sold their share after it spike"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":382326195671112,"gmtCreate":1734372676287,"gmtModify":1734416061803,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4156648821928502","idStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$</a> i might need a vaccine to hold it for long <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a><a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> ","listText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$</a> i might need a vaccine to hold it for long <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a><a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> ","text":"$Tonix Pharmaceuticals(TNXP)$ i might need a vaccine to hold it for long @TigerGPT$Tonix Pharmaceuticals(TNXP)$","images":[{"img":"https://community-static.tradeup.com/news/13e17785e1142024c8f2d6cec7b63255"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/382326195671112","repostId":"2492611699","repostType":2,"repost":{"id":"2492611699","kind":"highlight","weMediaInfo":{"introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the worldās largest and most trusted newswires.","home_visible":1,"media_name":"GlobeNewswire","id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"pubTimestamp":1734367200,"share":"https://ttm.financial/m/news/2492611699?lang=&edition=fundamental","pubTime":"2024-12-17 00:40","market":"hk","language":"en","title":"Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2492611699","media":"GlobeNewswire","summary":"Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 studies Granted Fast Track Designation by FDA in July 2024 for TNX-102 SL, a ","content":"<html><body><p><em>Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 studies</em></p> <p><em>Granted Fast Track Designation by FDA in July 2024 for TNX-102 SL, a centrally-acting, non-opioid analgesic; Fibromyalgia is a common chronic pain condition that affects mostly women</em></p> <p><em>Expect FDA decision in December 2024 on TNX-102 SL NDA acceptance for review and 2025 PDUFA date; If FDA-approved in 2025, TNX-102 SL would be the first new drug for fibromyalgia in more than 15 years</em></p> <p><em>Presented new data on potential mpox vaccine, TNX-801, in September and October 2024, demonstrating tolerability in immunocompromised animals; Previously reported studies showed a single-dose provided immune protection against a monkeypox challenge </em></p> <p><em>Awarded U.S. Department of Defense (DoD) contract for up to $34 million over five years in July 2024 to develop a broad-spectrum antiviral drug; Received first payment from DTRA</em></p> <p>CHATHAM, N.J., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced financial results for the third quarter ended September 30, 2024, and provided an overview of recent operational highlights.</p> <p>āWith our recent NDA submission to the U.S. Food and Drug Administration (FDA), Tonix is excited about the potential of TNX-102 SL to become the first new drug treatment option in more than 15 years for the roughly 10 million adults in the U.S. suffering from fibromyalgia,ā said Seth Lederman, M.D., Chief Executive Officer of Tonix. āFDA awarded TNX-102 SL Fast Track designation in the third quarter of 2024, which is intended to expedite FDA review of important new drugs to fill unmet needs for serious conditions. We look forward to next steps with FDA. If the NDA filing is accepted in December, we expect a decision on the marketing approval of TNX-102 SL for fibromyalgia in 2025.ā</p> <p>Dr. Lederman continued, āAs we continue to advance key pipeline products through a capital efficient strategy, we are excited to have announced collaborations with world-class institutions to advance the development of TNX-801, a potential mpox vaccine whose single-dose administration and other characteristics align closely with The World Health Organizationās preferred target product profile (TPP) criteria for mpox vaccines. The World Health Organization (WHO) previously announced the growing number of mpox cases constitutes a public health emergency of international concern (PHEIC), with clade 1b mpox strains now detected in 16 countries in Africa as well as in Sweden, Thailand, Singapore, India, England and Germany.ā</p> <p><strong>Key Product Candidates* -- Recent Highlights </strong></p> <p><em><u>Central Nervous System (CNS) Pipeline</u></em></p> <p><em>TNX-102 SL (cyclobenzaprine HCl sublingual tablets): 5.6 mg, once-daily at bedtime small molecule for the management of fibromyalgia (FM) ā a centrally-acting, non-opioid analgesic.</em></p> <ul type=\"disc\"><li>In October 2024, Tonix announced submission of the TNX-102 SL New Drug Application (NDA) for fibromyalgia to the FDA. The submission was based upon two Phase 3 studies of TNX-102 SL in fibromyalgia that showed statically significant reduction in the chronic, widespread pain associated with fibromyalgia. If approved by the FDA, TNX-102 SL would be the first member of a new class of analgesic drugs for fibromyalgia and the first new drug available for treating fibromyalgia in more than 15 years. Fibromyalgia affects more than 10 million adults in the U.S., most of whom are women.</li><li>In September 2024, at the 11th Global Conference on Pharmaceutics and Novel Drug Delivery Systems (PDDS 2024), the Company announced data highlighting the proprietary formulation technology and pharmacokinetic properties of TNX-102 SL, including composition and methods patents based on the proprietary eutectic<sup>1</sup> formulation of TNX-102 SL that are expected to provide market exclusivity until at least 2034 in the U.S., EU, Japan, China and other jurisdictions. The eutectic protects cyclobenzaprine HCl from interacting with the basifying agent that is also part of the formulation and required for efficient transmucosal absorption. The formulation of TNX-102 SL was designed specifically for sublingual administration and transmucosal absorption for bedtime dosing to target disturbed sleep, improve pain and other fibromyalgia symptoms, while reducing the risk of daytime somnolence.</li><li>In August 2024, at both the DoDās 2024 Military Health System Research Symposium (MHSRS), and at the International Association for the Study of Painās (IASPās) 2024 World Congress on Pain, Tonix announced additional data and analyses of TNX-102 SL for the management of fibromyalgia. TNX-102 SL had met the pre-specified primary endpoint in the Phase 3 RESILIENT study, significantly reducing daily pain compared to placebo (p-value=0.00005) in participants with fibromyalgia while demonstrating broad syndromal benefits with statistically significant improvement in all six pre-specified key secondary endpoints, including those related to improving sleep quality, reducing fatigue, and improving patient global ratings and overall fibromyalgia symptoms and function. TNX-102 SL was well tolerated with an adverse event profile comparable to prior studies and no new safety signals were observed.<br/></li><li>In July 2024, Tonix noted that, based on the new definition of Long COVID by the U.S. National Academies of Sciences, Engineering and Medicine (NASEM), fibromyalgia is a ādiagnosable conditionā in people suffering from Long COVID. The Company believes that diagnosing fibromyalgia in Long COVID patients will increase the potential market for TNX-102 SL following approval as compared to market estimates from before the COVID-19 pandemic.<br/></li></ul> <p><em>TNX-102 SL for the treatment of acute stress reaction (ASR) and acute stress disorder (ASD), and prophylaxis against development of posttraumatic stress disorder (PTSD)</em></p> <ul type=\"disc\"><li>In August 2024 at the DoDās MHSRS conference, the Company presented clinical data and rationale supporting the potential for TNX-102 SL to be studied for the treatment of ASR and prevention of PTSD. Prior studies showed that treatment with TNX-102 SL showed effects on sleep and PTSD symptoms in PTSD patients at two and four weeks<sup>1</sup>. This supportive data on the effects of TNX-102 SL on reducing PTSD symptoms suggest early intervention immediately after trauma using TNX-102 SL has the potential to reduce ASR/ASD symptoms which are similar to those of PTSD<sup>2</sup><sup>,</sup><sup>3</sup>. Data from these trials support testing of TNX-102 SL within 24 hours of index trauma for effects on ASR symptoms and the subsequent incidence of PTSD.</li><li>The DoD-funded Optimizing Acute Stress Reaction Interventions (OASIS) trial will be conducted by the University of North Carolina under an investigator-initiated investigational new drug (IND) application. The OASIS trial will examine the safety and efficacy of TNX-102 SL to reduce adverse posttraumatic neuropsychiatric sequelae among patients in the emergency department (ED) after a motor vehicle collision. Fourteen days of bedtime TNX-102 SL will be dosed and tested in the immediate aftermath of motor vehicle collision. The study will test the potential for TNX-102 SL to target trauma-related sleep disturbance and its ability to facilitate recovery from ASR and to prevent PTSD. The results may ultimately provide military personnel with a new treatment option that, when administered in the early aftermath of a traumatic event to individuals with ASR symptoms, improves warfighter function.</li></ul> <p><em>TNX-1300 (recombinant double mutant cocaine esterase): biologic for life-threatening cocaine intoxication</em></p> <ul type=\"disc\"><li>Tonix announced the first patient in the Phase 2 CATALYST study of TNX-1300 for the treatment of cocaine intoxication was enrolled in August 2024. CATALYST is a Phase 2 single-blind, placebo-controlled, proof-of-concept study in patients presenting to the emergency department. Topline results are expected in the first half of 2025.<br/></li><li>The National Institutes of Health (NIH)ās National Institute of Drug Abuse (NIDA) previously awarded Tonix a Cooperative Agreement grant for approximately $5 million from to support development of TNX-1300.<br/></li><li>TNX-1300 has been granted Breakthrough Therapy designation by the FDA.</li></ul> <p><em><u>Infectious Disease Pipeline</u></em></p> <p><em>TNX-801 (recombinant horsepox virus, live vaccine): potential vaccine to protect against mpox disease and smallpox.</em></p> <ul type=\"disc\"><li>In September 2024, at the DoDās MHSRS conference and in October 2024 at the World Vaccine Congress in Barcelona, Spain, Tonix presented new data on potential mpox vaccine, TNX-801, demonstrating tolerability and no evidence of spreading to blood or tissues, even at high doses, in immunocompromised animals. TNX-801 is an attenuated live-virus vaccine based on synthesized horsepox that has been shown to provide single-dose immune protection against a monkeypox challenge. After a single-dose vaccination, TNX-801 prevented clinical disease and lesions, and also decreased shedding in the mouth and lungs of non-human primates after a lethal challenge with Clade Ia monkeypox. These findings are consistent with TNX-801 inducing mucosal immunity and suggest TNX-801 has the ability to block forward transmission.</li><li>In August 2024, the WHO determined that the upsurge of mpox in a growing number of countries in Africa constitutes a public health emergency of international concern (PHEIC), the second such declaration in the past two years in response to transmission of the virus. Mpox cases of the new clade 1b mpox have since also been detected in Sweden, Thailand, Singapore, India, Germany and England.</li><li>In September 2024, the Company announced that the WHOās preferred TPP aligns with the characteristics of TNX-801. Key elements of the WHO draft TPP include single-dose, durable protection, administration without special equipment, and stability at ambient temperature. Other potential beneficial characteristics include the ability to limit forward transmission, use in case-contact vaccination strategies and suitability for use in immunocompromised individuals.<br/></li></ul> <p>Footnotes:</p> <ol><li><em>The TNX-102 SL eutectic is a composition of matter based on co-penetration of cyclobenzaprine HCl and mannitol crystals and protected by 5 issued U.S patents: Nos. 9,636,408; 9,956,188; 10,117,936; 10,864,175; 11,839,594; 9,918,948; 11,826,321.</em><br/></li><li><em>Sullivan GM, et al. Randomized clinical trial of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related PTSD and the role of sleep quality in treatment response. Psychiatry Res. 2021 Jul;301:113974.</em><br/></li><li><em>Parmenter ME, et al. A phase 3, randomized, placebo-controlled, trial to evaluate the efficacy and safety of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related posttraumatic stress disorder. Psychiatry Res. 2024 (In Press). https://doi.org/10.1016/j.psychres.2024.115764</em><br/></li></ol> <p><strong>Corporate and Partnerships ā Recent Highlights</strong></p> <ul type=\"disc\"><li>In November 2024, the Company announced that it has entered into a sponsored research agreement with the Kenya Medical Research Institute (KEMRI) to design, plan and seek regulatory approval for a Phase I clinical study in Kenya to test the safety, tolerability, and immunogenicity of TNX-801 (horsepox, live virus) as a vaccine to prevent mpox and smallpox. Tonix is expected be the sponsor and KEMRI is expected to lead the execution of the proposed clinical trial.<br/><br/></li><li>In October 2024, the Company announced it entered into an artificial intelligence and machine learning drug discovery collaboration with X-Chem, Inc., a leader in small molecule drug discovery, to accelerate the development of small molecules as orally available host-targeted broad-spectrum medical countermeasures. Tonixās TNX-4200 antiviral program focuses on the development of oral CD45 phosphatase inhibitors, with broad-spectrum activity against a range of viral families.<br/><br/></li><li>In September 2024, Tonix announced the appointment of Thomas Englese as its new Executive Vice President, Commercial Operations. Mr. Englese brings significant leadership to Tonix across several functions, including commercial operations, sales and marketing, and launching and managing major brands through all stages of commercialization.Ā Ā <br/><br/></li><li>In August 2024, the Company announced a collaboration with Bilthoven Biologics (Bbio) to develop GMP manufacturing processes for TNX-801 as a potential mpox vaccine. Bbio is part of the worldās largest vaccine manufacturer, the Cyrus Poonawalla Group, which also includes the Serum Institute of India.Ā Ā <br/><br/></li><li>In July 2024, Tonix announced it had been awarded a DoD contract with a potential for up to $34 million over five years by DoDās Defense Threat Reduction Agency (DTRA). The objective of the contract is to develop small molecule broad-spectrum antiviral agents for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonixās program will focus on optimization and development of its TNX-4200 program, to develop an orally available CD45 antagonist, with broad-spectrum efficacy against a range of viral families through preclinical evaluation. The program is expected to establish physicochemical properties, pharmacokinetics, and safety attributes to support an IIND submission and to fund a first-in-human Phase 1 clinical study.<br/></li></ul> <p><strong>Marketed Products ā Recent Highlights</strong></p> <ul type=\"disc\"><li>In September 2024, Tonix announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 12,097,183 to the Company, claiming use of a pre-filled autoinjector comprising a composition of ZembraceĀ® SymTouchĀ® for treating migraines via subcutaneous administration. This patent, excluding possible patent term extensions, is expected to fortify protection and market exclusivity into 2036.</li><li>Tonix announced that the USPTO issued U.S. Patent No. 12,090,139 to the Company, claiming a pharmaceutical composition, a method of treating migraine via intranasal administration, and an intranasal delivery system for TosymraĀ®. This patent is expected to fortify protection and market exclusivity into 2030.</li></ul> <p>Tonix Medicines launched a national educational campaign focusing on the link between migraine, gastroparesis, and the need for non-oral acute migraine therapies. Tonix Medicines is the only manufacturer with both a branded injectable and nasal spray indicated for the acute treatment of migraine with or without aura in adults.</p> <p><strong>Financial - Recent Highlight</strong></p> <p>As of September 30, 2024, Tonix had approximately $28.2 million of cash and cash equivalents, compared to approximately $24.9 million as of December 31, 2023. Additionally, Tonix had inventory totaling approximately $7.9 million as of September 30, 2024. Net cash used in operations was approximately $46.3 million for the nine months ended September 30, 2024, compared to approximately $79.7 million for the same period in 2023. Cash used in investing activities for the nine months ended September 30, 2024 was approximately $117,000 compared to $28.6 million for the same period in 2023.</p> <p>In July 2024, Tonix received net proceeds of approximately $3.5 million in a securities offering with certain institutional and retail investors. Additionally, during the three months ended September 30, 2024, Tonix sold approximately 134.5 million shares of common stock under the 2024 ATM Sales Agreement for net proceeds of approximately $41.8 million.</p> <p><u>Third Quarter 2024 Financial Results</u></p> <p>Net product revenue for the third quarter 2024 was approximately $2.8 million. Net product revenue consisted of combined net sales of ZembraceĀ® SymTouchĀ® and TosymraĀ®, which were acquired from Upsher-Smith Laboratories, LLC on June 30, 2023. Cost of sales for the third quarter 2024 was approximately $1.6 million.</p> <p>During the three months ended September 30, 2024, Tonix received its first payment from DTRA as part of its previously announced award from DTRA for up to $34 million over five years.</p> <p>Research and development expenses for the third quarter 2024 were approximately $9.1 million, compared to $21.0 million for the same period in 2023. This decrease is predominantly due to lower clinical, non-clinical and manufacturing expenses aligned with the Companyās capital efficient strategy.</p> <p>Selling, general and administrative expenses for the third quarter 2024 were approximately $7.7 million, compared to $8.7 million for the same period in 2023. The decrease was primarily due to lower employee-related expenses, transactional services and sales and marketing expenses partially offset by an increase in professional fees.</p> <p>Net loss available to common stockholders was approximately $14.2 million, or $0.23 per share, basic and diluted, for the third quarter 2024, compared to net loss available to common stockholders of $28.0 million, or $38.63 per share, basic and diluted, for the same period in 2023. The basic and diluted weighted average common shares outstanding for the third quarter 2024 was 62,122,283 compared to 724,190 shares for the same period in 2023.</p> <p><strong>Tonix Pharmaceuticals Holding Corp.</strong><sup><strong>*</strong></sup><br/>Tonix is a fully-integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges. Tonixās development portfolio is focused on central nervous system (CNS) disorders. Tonixās priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia. The FDA has granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. We expect an FDA decision on the acceptance of the NDA for review and a PDUFA date in December and if accepted, a decision on NDA approval in 2025. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonixās CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has FDA Breakthrough Therapy designation and its development is supported by a grant from the U.S. National Institute of Drug Abuse and Addiction. Tonixās immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease, including TNX-2900 for Prader-Willi syndrome, and infectious disease, including a vaccine for mpox, TNX-801. Tonix recently announced a contract with the U.S. DoDās Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, MD. Tonix Medicines, our commercial subsidiary, markets ZembraceĀ® SymTouchĀ® (sumatriptan injection) 3 mg and TosymraĀ® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.</p> <p>* Tonixās product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.</p> <p>Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.</p> <p>This press release and further information about Tonix can be found at <u>www.tonixpharma.com</u>.</p> <p><strong>Forward Looking Statements</strong></p> <p>Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as āanticipate,ā ābelieve,ā āforecast,ā āestimate,ā āexpect,ā and āintend,ā among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the āSECā) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.</p> <table><tr><td colspan=\"18\"><strong>TONIX PHARMACEUTICALS HOLDING CORP.</strong>Ā <br/><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</strong><br/><strong>(In Thousands, Except Share and Per Share Amounts)</strong><br/><strong>(unaudited)</strong><strong><br/></strong></td></tr><tr><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td></tr><tr><td>Ā </td><td>Ā </td><td>Ā </td><td colspan=\"6\"><strong>Three Months Ended</strong><br/><strong>September 30,</strong><strong><br/></strong></td><td>Ā </td><td>Ā </td><td colspan=\"6\"><strong>Nine Months Ended</strong><br/><strong>September 30,</strong><strong><br/></strong></td><td>Ā </td></tr><tr><td>Ā </td><td>Ā </td><td>Ā </td><td colspan=\"2\"><strong>2024</strong><strong><br/></strong></td><td>Ā </td><td>Ā </td><td colspan=\"2\"><strong>2023</strong><strong><br/></strong></td><td>Ā </td><td>Ā </td><td colspan=\"2\"><strong>2024</strong><strong><br/></strong></td><td>Ā </td><td>Ā </td><td colspan=\"2\"><strong>2023</strong><strong><br/></strong></td><td>Ā </td></tr><tr><td>REVENUE:</td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td></tr><tr><td>Product revenue, net</td><td>Ā </td><td>Ā </td><td>$</td><td>2,822</td><td>Ā </td><td>Ā </td><td>$</td><td>3,989</td><td>Ā </td><td>Ā </td><td>$</td><td>7,512</td><td>Ā </td><td>Ā </td><td>$</td><td>3,989</td><td>Ā </td></tr><tr><td>COSTS AND EXPENSES:</td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td></tr><tr><td>Cost of revenue</td><td>Ā </td><td>Ā </td><td>Ā </td><td>1,555</td><td>Ā </td><td>Ā </td><td>Ā </td><td>2,374</td><td>Ā </td><td>Ā </td><td>Ā </td><td>6,582</td><td>Ā </td><td>Ā </td><td>Ā </td><td>2,374</td><td>Ā </td></tr><tr><td>Research and development</td><td>Ā </td><td>Ā </td><td>Ā </td><td>9,114</td><td>Ā </td><td>Ā </td><td>Ā </td><td>21,050</td><td>Ā </td><td>Ā </td><td>Ā </td><td>31,675</td><td>Ā </td><td>Ā </td><td>Ā </td><td>69,535</td><td>Ā </td></tr><tr><td>Selling, general and administrative</td><td>Ā </td><td>Ā </td><td>Ā </td><td>7,707</td><td>Ā </td><td>Ā </td><td>Ā </td><td>8,712</td><td>Ā </td><td>Ā </td><td>Ā </td><td>24,519</td><td>Ā </td><td>Ā </td><td>Ā </td><td>23,131</td><td>Ā </td></tr><tr><td>Asset impairment charges</td><td>Ā </td><td>Ā </td><td>Ā </td><td>ā</td><td>Ā </td><td>Ā </td><td>Ā </td><td>ā</td><td>Ā </td><td>Ā </td><td>Ā </td><td>58,957</td><td>Ā </td><td>Ā </td><td>Ā </td><td>ā</td><td>Ā </td></tr><tr><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>18,376</td><td>Ā </td><td>Ā </td><td>Ā </td><td>32,136</td><td>Ā </td><td>Ā </td><td>Ā </td><td>121,733</td><td>Ā </td><td>Ā </td><td>Ā </td><td>95,040</td><td>Ā </td></tr><tr><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td></tr><tr><td>Operating loss</td><td>Ā </td><td>Ā </td><td>Ā </td><td>(15,554</td><td>)</td><td>Ā </td><td>Ā </td><td>(28,147</td><td>)</td><td>Ā </td><td>Ā </td><td>(114,221</td><td>)</td><td>Ā </td><td>Ā </td><td>(91,051</td><td>)</td></tr><tr><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td></tr><tr><td>Grant income</td><td>Ā </td><td>Ā </td><td>Ā </td><td>1,668</td><td>Ā </td><td>Ā </td><td>Ā </td><td>ā</td><td>Ā </td><td>Ā </td><td>Ā </td><td>1,668</td><td>Ā </td><td>Ā </td><td>Ā </td><td>ā</td><td>Ā </td></tr><tr><td>Gain on change in fair value of warrant liabilities</td><td>Ā </td><td>Ā </td><td>Ā </td><td>ā</td><td>Ā </td><td>Ā </td><td>Ā </td><td>ā</td><td>Ā </td><td>Ā </td><td>Ā </td><td>6,150</td><td>Ā </td><td>Ā </td><td>Ā </td><td>ā</td><td>Ā </td></tr><tr><td>Other (expense) income, net</td><td>Ā </td><td>Ā </td><td>Ā </td><td>(327</td><td>)</td><td>Ā </td><td>Ā </td><td>172</td><td>Ā </td><td>Ā </td><td>Ā </td><td>(1,525</td><td>)</td><td>Ā </td><td>Ā </td><td>1,715</td><td>Ā </td></tr><tr><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td></tr><tr><td>Net loss available to common stockholders</td><td>Ā </td><td>Ā </td><td>$</td><td>(14,213</td><td>)</td><td>Ā </td><td>$</td><td>(27,975</td><td>)</td><td>Ā </td><td>$</td><td>(107,928</td><td>)</td><td>Ā </td><td>$</td><td>(89,336</td><td>)</td></tr><tr><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td></tr><tr><td>Net loss per common share, basic and diluted</td><td>Ā </td><td>Ā </td><td>$</td><td>(0.23</td><td>)</td><td>Ā </td><td>$</td><td>(38.63</td><td>)</td><td>Ā </td><td>$</td><td>(4.66</td><td>)</td><td>Ā </td><td>$</td><td>(143.47</td><td>)</td></tr><tr><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td></tr><tr><td>Weighted average common shares outstanding, basic and diluted</td><td>Ā </td><td>Ā </td><td>Ā </td><td>62,122,283</td><td>Ā </td><td>Ā </td><td>Ā </td><td>724,190</td><td>Ā </td><td>Ā </td><td>Ā </td><td>23,136,172</td><td>Ā </td><td>Ā </td><td>Ā </td><td>622,684</td><td>Ā </td></tr><tr><td colspan=\"18\">Ā </td></tr></table> <table><tr><td colspan=\"6\"><strong>TONIX PHARMACEUTICALS HOLDING CORP.</strong><br/><strong>CONDENSED CONSOLIDATED BALANCE SHEETS</strong><br/><strong> (In Thousands)</strong><br/><strong>(Unaudited)</strong></td></tr><tr><td colspan=\"6\">Ā </td></tr><tr><td><strong>Ā </strong></td><td colspan=\"2\"><strong>September 30, 2024</strong><strong><br/></strong></td><td>Ā </td><td colspan=\"2\"><strong>December 31, 2023<sup><strong>1</strong></sup></strong><strong><br/></strong></td></tr><tr><td><strong>Assets</strong></td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td></tr><tr><td>Cash and cash equivalents</td><td>$Ā Ā 28,233</td><td>Ā </td><td>Ā </td><td>$Ā Ā 24,948</td><td>Ā </td></tr><tr><td>Accounts Receivable, net</td><td>4,013</td><td>Ā </td><td>Ā </td><td>-</td><td>Ā </td></tr><tr><td>Inventory</td><td>7,931</td><td>Ā </td><td>Ā </td><td>13,639</td><td>Ā </td></tr><tr><td>Prepaid expenses and other</td><td>10,366</td><td>Ā </td><td>Ā </td><td>9,181</td><td>Ā </td></tr><tr><td>Total current assets</td><td>50,543</td><td>Ā </td><td>Ā </td><td>47,768</td><td>Ā </td></tr><tr><td>Other non-current assets</td><td>44,446</td><td>Ā </td><td>Ā </td><td>106,689</td><td>Ā </td></tr><tr><td>Total assets</td><td>$Ā Ā 94,989</td><td>Ā </td><td>Ā </td><td>$Ā Ā 154,457</td><td>Ā </td></tr><tr><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td></tr><tr><td><strong>Liabilities and stockholders' equity</strong></td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td></tr><tr><td>Total liabilities</td><td>$Ā Ā 20,778</td><td>Ā </td><td>Ā </td><td>$Ā Ā 48,932</td><td>Ā </td></tr><tr><td>Stockholders' equity</td><td>74,211</td><td>Ā </td><td>Ā </td><td>105,525</td><td>Ā </td></tr><tr><td>Total liabilities and stockholders' equity</td><td>$Ā Ā 94,989</td><td>Ā </td><td>Ā </td><td>$Ā Ā 154,457</td><td>Ā </td></tr><tr><td colspan=\"6\">Ā </td></tr><tr><td colspan=\"6\"><sup>1</sup>The condensed consolidated balance sheet for the year ended December 31, 2023 has been derived from the audited financial statements but do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.</td></tr><tr><td colspan=\"6\">Ā </td></tr></table> <p><strong>Investor Contact</strong></p> <p>Jessica Morris<br/>Tonix Pharmaceuticals<br/><u>investor.relations@tonixpharma.com</u> <br/>(862) 904-8182</p> <p>Peter Vozzo<br/>ICR Healthcare<br/><u>peter.vozzo@westwicke.com</u> <br/>(443) 213-0505</p> <p><strong>Media Contact</strong></p> <p>Ray Jordan<br/>Putnam Insights<br/>ray@putnaminsights.com<br/>(949) 245-5432</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/MDk5YmE2ZGItNTRmMy00Y2JiLWExOTItNDIxODhkZjhjMjc4LTEwMjI2ODU=/tiny/Tonix-Pharmaceuticals-Holding-.png\"/></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time\">2024-12-17 00:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><em>Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 studies</em></p> <p><em>Granted Fast Track Designation by FDA in July 2024 for TNX-102 SL, a centrally-acting, non-opioid analgesic; Fibromyalgia is a common chronic pain condition that affects mostly women</em></p> <p><em>Expect FDA decision in December 2024 on TNX-102 SL NDA acceptance for review and 2025 PDUFA date; If FDA-approved in 2025, TNX-102 SL would be the first new drug for fibromyalgia in more than 15 years</em></p> <p><em>Presented new data on potential mpox vaccine, TNX-801, in September and October 2024, demonstrating tolerability in immunocompromised animals; Previously reported studies showed a single-dose provided immune protection against a monkeypox challenge </em></p> <p><em>Awarded U.S. Department of Defense (DoD) contract for up to $34 million over five years in July 2024 to develop a broad-spectrum antiviral drug; Received first payment from DTRA</em></p> <p>CHATHAM, N.J., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced financial results for the third quarter ended September 30, 2024, and provided an overview of recent operational highlights.</p> <p>āWith our recent NDA submission to the U.S. Food and Drug Administration (FDA), Tonix is excited about the potential of TNX-102 SL to become the first new drug treatment option in more than 15 years for the roughly 10 million adults in the U.S. suffering from fibromyalgia,ā said Seth Lederman, M.D., Chief Executive Officer of Tonix. āFDA awarded TNX-102 SL Fast Track designation in the third quarter of 2024, which is intended to expedite FDA review of important new drugs to fill unmet needs for serious conditions. We look forward to next steps with FDA. If the NDA filing is accepted in December, we expect a decision on the marketing approval of TNX-102 SL for fibromyalgia in 2025.ā</p> <p>Dr. Lederman continued, āAs we continue to advance key pipeline products through a capital efficient strategy, we are excited to have announced collaborations with world-class institutions to advance the development of TNX-801, a potential mpox vaccine whose single-dose administration and other characteristics align closely with The World Health Organizationās preferred target product profile (TPP) criteria for mpox vaccines. The World Health Organization (WHO) previously announced the growing number of mpox cases constitutes a public health emergency of international concern (PHEIC), with clade 1b mpox strains now detected in 16 countries in Africa as well as in Sweden, Thailand, Singapore, India, England and Germany.ā</p> <p><strong>Key Product Candidates* -- Recent Highlights </strong></p> <p><em><u>Central Nervous System (CNS) Pipeline</u></em></p> <p><em>TNX-102 SL (cyclobenzaprine HCl sublingual tablets): 5.6 mg, once-daily at bedtime small molecule for the management of fibromyalgia (FM) ā a centrally-acting, non-opioid analgesic.</em></p> <ul type=\"disc\"><li>In October 2024, Tonix announced submission of the TNX-102 SL New Drug Application (NDA) for fibromyalgia to the FDA. The submission was based upon two Phase 3 studies of TNX-102 SL in fibromyalgia that showed statically significant reduction in the chronic, widespread pain associated with fibromyalgia. If approved by the FDA, TNX-102 SL would be the first member of a new class of analgesic drugs for fibromyalgia and the first new drug available for treating fibromyalgia in more than 15 years. Fibromyalgia affects more than 10 million adults in the U.S., most of whom are women.</li><li>In September 2024, at the 11th Global Conference on Pharmaceutics and Novel Drug Delivery Systems (PDDS 2024), the Company announced data highlighting the proprietary formulation technology and pharmacokinetic properties of TNX-102 SL, including composition and methods patents based on the proprietary eutectic<sup>1</sup> formulation of TNX-102 SL that are expected to provide market exclusivity until at least 2034 in the U.S., EU, Japan, China and other jurisdictions. The eutectic protects cyclobenzaprine HCl from interacting with the basifying agent that is also part of the formulation and required for efficient transmucosal absorption. The formulation of TNX-102 SL was designed specifically for sublingual administration and transmucosal absorption for bedtime dosing to target disturbed sleep, improve pain and other fibromyalgia symptoms, while reducing the risk of daytime somnolence.</li><li>In August 2024, at both the DoDās 2024 Military Health System Research Symposium (MHSRS), and at the International Association for the Study of Painās (IASPās) 2024 World Congress on Pain, Tonix announced additional data and analyses of TNX-102 SL for the management of fibromyalgia. TNX-102 SL had met the pre-specified primary endpoint in the Phase 3 RESILIENT study, significantly reducing daily pain compared to placebo (p-value=0.00005) in participants with fibromyalgia while demonstrating broad syndromal benefits with statistically significant improvement in all six pre-specified key secondary endpoints, including those related to improving sleep quality, reducing fatigue, and improving patient global ratings and overall fibromyalgia symptoms and function. TNX-102 SL was well tolerated with an adverse event profile comparable to prior studies and no new safety signals were observed.<br/></li><li>In July 2024, Tonix noted that, based on the new definition of Long COVID by the U.S. National Academies of Sciences, Engineering and Medicine (NASEM), fibromyalgia is a ādiagnosable conditionā in people suffering from Long COVID. The Company believes that diagnosing fibromyalgia in Long COVID patients will increase the potential market for TNX-102 SL following approval as compared to market estimates from before the COVID-19 pandemic.<br/></li></ul> <p><em>TNX-102 SL for the treatment of acute stress reaction (ASR) and acute stress disorder (ASD), and prophylaxis against development of posttraumatic stress disorder (PTSD)</em></p> <ul type=\"disc\"><li>In August 2024 at the DoDās MHSRS conference, the Company presented clinical data and rationale supporting the potential for TNX-102 SL to be studied for the treatment of ASR and prevention of PTSD. Prior studies showed that treatment with TNX-102 SL showed effects on sleep and PTSD symptoms in PTSD patients at two and four weeks<sup>1</sup>. This supportive data on the effects of TNX-102 SL on reducing PTSD symptoms suggest early intervention immediately after trauma using TNX-102 SL has the potential to reduce ASR/ASD symptoms which are similar to those of PTSD<sup>2</sup><sup>,</sup><sup>3</sup>. Data from these trials support testing of TNX-102 SL within 24 hours of index trauma for effects on ASR symptoms and the subsequent incidence of PTSD.</li><li>The DoD-funded Optimizing Acute Stress Reaction Interventions (OASIS) trial will be conducted by the University of North Carolina under an investigator-initiated investigational new drug (IND) application. The OASIS trial will examine the safety and efficacy of TNX-102 SL to reduce adverse posttraumatic neuropsychiatric sequelae among patients in the emergency department (ED) after a motor vehicle collision. Fourteen days of bedtime TNX-102 SL will be dosed and tested in the immediate aftermath of motor vehicle collision. The study will test the potential for TNX-102 SL to target trauma-related sleep disturbance and its ability to facilitate recovery from ASR and to prevent PTSD. The results may ultimately provide military personnel with a new treatment option that, when administered in the early aftermath of a traumatic event to individuals with ASR symptoms, improves warfighter function.</li></ul> <p><em>TNX-1300 (recombinant double mutant cocaine esterase): biologic for life-threatening cocaine intoxication</em></p> <ul type=\"disc\"><li>Tonix announced the first patient in the Phase 2 CATALYST study of TNX-1300 for the treatment of cocaine intoxication was enrolled in August 2024. CATALYST is a Phase 2 single-blind, placebo-controlled, proof-of-concept study in patients presenting to the emergency department. Topline results are expected in the first half of 2025.<br/></li><li>The National Institutes of Health (NIH)ās National Institute of Drug Abuse (NIDA) previously awarded Tonix a Cooperative Agreement grant for approximately $5 million from to support development of TNX-1300.<br/></li><li>TNX-1300 has been granted Breakthrough Therapy designation by the FDA.</li></ul> <p><em><u>Infectious Disease Pipeline</u></em></p> <p><em>TNX-801 (recombinant horsepox virus, live vaccine): potential vaccine to protect against mpox disease and smallpox.</em></p> <ul type=\"disc\"><li>In September 2024, at the DoDās MHSRS conference and in October 2024 at the World Vaccine Congress in Barcelona, Spain, Tonix presented new data on potential mpox vaccine, TNX-801, demonstrating tolerability and no evidence of spreading to blood or tissues, even at high doses, in immunocompromised animals. TNX-801 is an attenuated live-virus vaccine based on synthesized horsepox that has been shown to provide single-dose immune protection against a monkeypox challenge. After a single-dose vaccination, TNX-801 prevented clinical disease and lesions, and also decreased shedding in the mouth and lungs of non-human primates after a lethal challenge with Clade Ia monkeypox. These findings are consistent with TNX-801 inducing mucosal immunity and suggest TNX-801 has the ability to block forward transmission.</li><li>In August 2024, the WHO determined that the upsurge of mpox in a growing number of countries in Africa constitutes a public health emergency of international concern (PHEIC), the second such declaration in the past two years in response to transmission of the virus. Mpox cases of the new clade 1b mpox have since also been detected in Sweden, Thailand, Singapore, India, Germany and England.</li><li>In September 2024, the Company announced that the WHOās preferred TPP aligns with the characteristics of TNX-801. Key elements of the WHO draft TPP include single-dose, durable protection, administration without special equipment, and stability at ambient temperature. Other potential beneficial characteristics include the ability to limit forward transmission, use in case-contact vaccination strategies and suitability for use in immunocompromised individuals.<br/></li></ul> <p>Footnotes:</p> <ol><li><em>The TNX-102 SL eutectic is a composition of matter based on co-penetration of cyclobenzaprine HCl and mannitol crystals and protected by 5 issued U.S patents: Nos. 9,636,408; 9,956,188; 10,117,936; 10,864,175; 11,839,594; 9,918,948; 11,826,321.</em><br/></li><li><em>Sullivan GM, et al. Randomized clinical trial of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related PTSD and the role of sleep quality in treatment response. Psychiatry Res. 2021 Jul;301:113974.</em><br/></li><li><em>Parmenter ME, et al. A phase 3, randomized, placebo-controlled, trial to evaluate the efficacy and safety of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related posttraumatic stress disorder. Psychiatry Res. 2024 (In Press). https://doi.org/10.1016/j.psychres.2024.115764</em><br/></li></ol> <p><strong>Corporate and Partnerships ā Recent Highlights</strong></p> <ul type=\"disc\"><li>In November 2024, the Company announced that it has entered into a sponsored research agreement with the Kenya Medical Research Institute (KEMRI) to design, plan and seek regulatory approval for a Phase I clinical study in Kenya to test the safety, tolerability, and immunogenicity of TNX-801 (horsepox, live virus) as a vaccine to prevent mpox and smallpox. Tonix is expected be the sponsor and KEMRI is expected to lead the execution of the proposed clinical trial.<br/><br/></li><li>In October 2024, the Company announced it entered into an artificial intelligence and machine learning drug discovery collaboration with X-Chem, Inc., a leader in small molecule drug discovery, to accelerate the development of small molecules as orally available host-targeted broad-spectrum medical countermeasures. Tonixās TNX-4200 antiviral program focuses on the development of oral CD45 phosphatase inhibitors, with broad-spectrum activity against a range of viral families.<br/><br/></li><li>In September 2024, Tonix announced the appointment of Thomas Englese as its new Executive Vice President, Commercial Operations. Mr. Englese brings significant leadership to Tonix across several functions, including commercial operations, sales and marketing, and launching and managing major brands through all stages of commercialization.Ā Ā <br/><br/></li><li>In August 2024, the Company announced a collaboration with Bilthoven Biologics (Bbio) to develop GMP manufacturing processes for TNX-801 as a potential mpox vaccine. Bbio is part of the worldās largest vaccine manufacturer, the Cyrus Poonawalla Group, which also includes the Serum Institute of India.Ā Ā <br/><br/></li><li>In July 2024, Tonix announced it had been awarded a DoD contract with a potential for up to $34 million over five years by DoDās Defense Threat Reduction Agency (DTRA). The objective of the contract is to develop small molecule broad-spectrum antiviral agents for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonixās program will focus on optimization and development of its TNX-4200 program, to develop an orally available CD45 antagonist, with broad-spectrum efficacy against a range of viral families through preclinical evaluation. The program is expected to establish physicochemical properties, pharmacokinetics, and safety attributes to support an IIND submission and to fund a first-in-human Phase 1 clinical study.<br/></li></ul> <p><strong>Marketed Products ā Recent Highlights</strong></p> <ul type=\"disc\"><li>In September 2024, Tonix announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 12,097,183 to the Company, claiming use of a pre-filled autoinjector comprising a composition of ZembraceĀ® SymTouchĀ® for treating migraines via subcutaneous administration. This patent, excluding possible patent term extensions, is expected to fortify protection and market exclusivity into 2036.</li><li>Tonix announced that the USPTO issued U.S. Patent No. 12,090,139 to the Company, claiming a pharmaceutical composition, a method of treating migraine via intranasal administration, and an intranasal delivery system for TosymraĀ®. This patent is expected to fortify protection and market exclusivity into 2030.</li></ul> <p>Tonix Medicines launched a national educational campaign focusing on the link between migraine, gastroparesis, and the need for non-oral acute migraine therapies. Tonix Medicines is the only manufacturer with both a branded injectable and nasal spray indicated for the acute treatment of migraine with or without aura in adults.</p> <p><strong>Financial - Recent Highlight</strong></p> <p>As of September 30, 2024, Tonix had approximately $28.2 million of cash and cash equivalents, compared to approximately $24.9 million as of December 31, 2023. Additionally, Tonix had inventory totaling approximately $7.9 million as of September 30, 2024. Net cash used in operations was approximately $46.3 million for the nine months ended September 30, 2024, compared to approximately $79.7 million for the same period in 2023. Cash used in investing activities for the nine months ended September 30, 2024 was approximately $117,000 compared to $28.6 million for the same period in 2023.</p> <p>In July 2024, Tonix received net proceeds of approximately $3.5 million in a securities offering with certain institutional and retail investors. Additionally, during the three months ended September 30, 2024, Tonix sold approximately 134.5 million shares of common stock under the 2024 ATM Sales Agreement for net proceeds of approximately $41.8 million.</p> <p><u>Third Quarter 2024 Financial Results</u></p> <p>Net product revenue for the third quarter 2024 was approximately $2.8 million. Net product revenue consisted of combined net sales of ZembraceĀ® SymTouchĀ® and TosymraĀ®, which were acquired from Upsher-Smith Laboratories, LLC on June 30, 2023. Cost of sales for the third quarter 2024 was approximately $1.6 million.</p> <p>During the three months ended September 30, 2024, Tonix received its first payment from DTRA as part of its previously announced award from DTRA for up to $34 million over five years.</p> <p>Research and development expenses for the third quarter 2024 were approximately $9.1 million, compared to $21.0 million for the same period in 2023. This decrease is predominantly due to lower clinical, non-clinical and manufacturing expenses aligned with the Companyās capital efficient strategy.</p> <p>Selling, general and administrative expenses for the third quarter 2024 were approximately $7.7 million, compared to $8.7 million for the same period in 2023. The decrease was primarily due to lower employee-related expenses, transactional services and sales and marketing expenses partially offset by an increase in professional fees.</p> <p>Net loss available to common stockholders was approximately $14.2 million, or $0.23 per share, basic and diluted, for the third quarter 2024, compared to net loss available to common stockholders of $28.0 million, or $38.63 per share, basic and diluted, for the same period in 2023. The basic and diluted weighted average common shares outstanding for the third quarter 2024 was 62,122,283 compared to 724,190 shares for the same period in 2023.</p> <p><strong>Tonix Pharmaceuticals Holding Corp.</strong><sup><strong>*</strong></sup><br/>Tonix is a fully-integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges. Tonixās development portfolio is focused on central nervous system (CNS) disorders. Tonixās priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia. The FDA has granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. We expect an FDA decision on the acceptance of the NDA for review and a PDUFA date in December and if accepted, a decision on NDA approval in 2025. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonixās CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has FDA Breakthrough Therapy designation and its development is supported by a grant from the U.S. National Institute of Drug Abuse and Addiction. Tonixās immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease, including TNX-2900 for Prader-Willi syndrome, and infectious disease, including a vaccine for mpox, TNX-801. Tonix recently announced a contract with the U.S. DoDās Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, MD. Tonix Medicines, our commercial subsidiary, markets ZembraceĀ® SymTouchĀ® (sumatriptan injection) 3 mg and TosymraĀ® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.</p> <p>* Tonixās product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.</p> <p>Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.</p> <p>This press release and further information about Tonix can be found at <u>www.tonixpharma.com</u>.</p> <p><strong>Forward Looking Statements</strong></p> <p>Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as āanticipate,ā ābelieve,ā āforecast,ā āestimate,ā āexpect,ā and āintend,ā among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the āSECā) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.</p> <table><tr><td colspan=\"18\"><strong>TONIX PHARMACEUTICALS HOLDING CORP.</strong>Ā <br/><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</strong><br/><strong>(In Thousands, Except Share and Per Share Amounts)</strong><br/><strong>(unaudited)</strong><strong><br/></strong></td></tr><tr><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td></tr><tr><td>Ā </td><td>Ā </td><td>Ā </td><td colspan=\"6\"><strong>Three Months Ended</strong><br/><strong>September 30,</strong><strong><br/></strong></td><td>Ā </td><td>Ā </td><td colspan=\"6\"><strong>Nine Months Ended</strong><br/><strong>September 30,</strong><strong><br/></strong></td><td>Ā </td></tr><tr><td>Ā </td><td>Ā </td><td>Ā </td><td colspan=\"2\"><strong>2024</strong><strong><br/></strong></td><td>Ā </td><td>Ā </td><td colspan=\"2\"><strong>2023</strong><strong><br/></strong></td><td>Ā </td><td>Ā </td><td colspan=\"2\"><strong>2024</strong><strong><br/></strong></td><td>Ā </td><td>Ā </td><td colspan=\"2\"><strong>2023</strong><strong><br/></strong></td><td>Ā </td></tr><tr><td>REVENUE:</td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td></tr><tr><td>Product revenue, net</td><td>Ā </td><td>Ā </td><td>$</td><td>2,822</td><td>Ā </td><td>Ā </td><td>$</td><td>3,989</td><td>Ā </td><td>Ā </td><td>$</td><td>7,512</td><td>Ā </td><td>Ā </td><td>$</td><td>3,989</td><td>Ā </td></tr><tr><td>COSTS AND EXPENSES:</td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td></tr><tr><td>Cost of revenue</td><td>Ā </td><td>Ā </td><td>Ā </td><td>1,555</td><td>Ā </td><td>Ā </td><td>Ā </td><td>2,374</td><td>Ā </td><td>Ā </td><td>Ā </td><td>6,582</td><td>Ā </td><td>Ā </td><td>Ā </td><td>2,374</td><td>Ā </td></tr><tr><td>Research and development</td><td>Ā </td><td>Ā </td><td>Ā </td><td>9,114</td><td>Ā </td><td>Ā </td><td>Ā </td><td>21,050</td><td>Ā </td><td>Ā </td><td>Ā </td><td>31,675</td><td>Ā </td><td>Ā </td><td>Ā </td><td>69,535</td><td>Ā </td></tr><tr><td>Selling, general and administrative</td><td>Ā </td><td>Ā </td><td>Ā </td><td>7,707</td><td>Ā </td><td>Ā </td><td>Ā </td><td>8,712</td><td>Ā </td><td>Ā </td><td>Ā </td><td>24,519</td><td>Ā </td><td>Ā </td><td>Ā </td><td>23,131</td><td>Ā </td></tr><tr><td>Asset impairment charges</td><td>Ā </td><td>Ā </td><td>Ā </td><td>ā</td><td>Ā </td><td>Ā </td><td>Ā </td><td>ā</td><td>Ā </td><td>Ā </td><td>Ā </td><td>58,957</td><td>Ā </td><td>Ā </td><td>Ā </td><td>ā</td><td>Ā </td></tr><tr><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>18,376</td><td>Ā </td><td>Ā </td><td>Ā </td><td>32,136</td><td>Ā </td><td>Ā </td><td>Ā </td><td>121,733</td><td>Ā </td><td>Ā </td><td>Ā </td><td>95,040</td><td>Ā </td></tr><tr><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td></tr><tr><td>Operating loss</td><td>Ā </td><td>Ā </td><td>Ā </td><td>(15,554</td><td>)</td><td>Ā </td><td>Ā </td><td>(28,147</td><td>)</td><td>Ā </td><td>Ā </td><td>(114,221</td><td>)</td><td>Ā </td><td>Ā </td><td>(91,051</td><td>)</td></tr><tr><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td></tr><tr><td>Grant income</td><td>Ā </td><td>Ā </td><td>Ā </td><td>1,668</td><td>Ā </td><td>Ā </td><td>Ā </td><td>ā</td><td>Ā </td><td>Ā </td><td>Ā </td><td>1,668</td><td>Ā </td><td>Ā </td><td>Ā </td><td>ā</td><td>Ā </td></tr><tr><td>Gain on change in fair value of warrant liabilities</td><td>Ā </td><td>Ā </td><td>Ā </td><td>ā</td><td>Ā </td><td>Ā </td><td>Ā </td><td>ā</td><td>Ā </td><td>Ā </td><td>Ā </td><td>6,150</td><td>Ā </td><td>Ā </td><td>Ā </td><td>ā</td><td>Ā </td></tr><tr><td>Other (expense) income, net</td><td>Ā </td><td>Ā </td><td>Ā </td><td>(327</td><td>)</td><td>Ā </td><td>Ā </td><td>172</td><td>Ā </td><td>Ā </td><td>Ā </td><td>(1,525</td><td>)</td><td>Ā </td><td>Ā </td><td>1,715</td><td>Ā </td></tr><tr><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td></tr><tr><td>Net loss available to common stockholders</td><td>Ā </td><td>Ā </td><td>$</td><td>(14,213</td><td>)</td><td>Ā </td><td>$</td><td>(27,975</td><td>)</td><td>Ā </td><td>$</td><td>(107,928</td><td>)</td><td>Ā </td><td>$</td><td>(89,336</td><td>)</td></tr><tr><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td></tr><tr><td>Net loss per common share, basic and diluted</td><td>Ā </td><td>Ā </td><td>$</td><td>(0.23</td><td>)</td><td>Ā </td><td>$</td><td>(38.63</td><td>)</td><td>Ā </td><td>$</td><td>(4.66</td><td>)</td><td>Ā </td><td>$</td><td>(143.47</td><td>)</td></tr><tr><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td></tr><tr><td>Weighted average common shares outstanding, basic and diluted</td><td>Ā </td><td>Ā </td><td>Ā </td><td>62,122,283</td><td>Ā </td><td>Ā </td><td>Ā </td><td>724,190</td><td>Ā </td><td>Ā </td><td>Ā </td><td>23,136,172</td><td>Ā </td><td>Ā </td><td>Ā </td><td>622,684</td><td>Ā </td></tr><tr><td colspan=\"18\">Ā </td></tr></table> <table><tr><td colspan=\"6\"><strong>TONIX PHARMACEUTICALS HOLDING CORP.</strong><br/><strong>CONDENSED CONSOLIDATED BALANCE SHEETS</strong><br/><strong> (In Thousands)</strong><br/><strong>(Unaudited)</strong></td></tr><tr><td colspan=\"6\">Ā </td></tr><tr><td><strong>Ā </strong></td><td colspan=\"2\"><strong>September 30, 2024</strong><strong><br/></strong></td><td>Ā </td><td colspan=\"2\"><strong>December 31, 2023<sup><strong>1</strong></sup></strong><strong><br/></strong></td></tr><tr><td><strong>Assets</strong></td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td></tr><tr><td>Cash and cash equivalents</td><td>$Ā Ā 28,233</td><td>Ā </td><td>Ā </td><td>$Ā Ā 24,948</td><td>Ā </td></tr><tr><td>Accounts Receivable, net</td><td>4,013</td><td>Ā </td><td>Ā </td><td>-</td><td>Ā </td></tr><tr><td>Inventory</td><td>7,931</td><td>Ā </td><td>Ā </td><td>13,639</td><td>Ā </td></tr><tr><td>Prepaid expenses and other</td><td>10,366</td><td>Ā </td><td>Ā </td><td>9,181</td><td>Ā </td></tr><tr><td>Total current assets</td><td>50,543</td><td>Ā </td><td>Ā </td><td>47,768</td><td>Ā </td></tr><tr><td>Other non-current assets</td><td>44,446</td><td>Ā </td><td>Ā </td><td>106,689</td><td>Ā </td></tr><tr><td>Total assets</td><td>$Ā Ā 94,989</td><td>Ā </td><td>Ā </td><td>$Ā Ā 154,457</td><td>Ā </td></tr><tr><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td></tr><tr><td><strong>Liabilities and stockholders' equity</strong></td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td><td>Ā </td></tr><tr><td>Total liabilities</td><td>$Ā Ā 20,778</td><td>Ā </td><td>Ā </td><td>$Ā Ā 48,932</td><td>Ā </td></tr><tr><td>Stockholders' equity</td><td>74,211</td><td>Ā </td><td>Ā </td><td>105,525</td><td>Ā </td></tr><tr><td>Total liabilities and stockholders' equity</td><td>$Ā Ā 94,989</td><td>Ā </td><td>Ā </td><td>$Ā Ā 154,457</td><td>Ā </td></tr><tr><td colspan=\"6\">Ā </td></tr><tr><td colspan=\"6\"><sup>1</sup>The condensed consolidated balance sheet for the year ended December 31, 2023 has been derived from the audited financial statements but do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.</td></tr><tr><td colspan=\"6\">Ā </td></tr></table> <p><strong>Investor Contact</strong></p> <p>Jessica Morris<br/>Tonix Pharmaceuticals<br/><u>investor.relations@tonixpharma.com</u> <br/>(862) 904-8182</p> <p>Peter Vozzo<br/>ICR Healthcare<br/><u>peter.vozzo@westwicke.com</u> <br/>(443) 213-0505</p> <p><strong>Media Contact</strong></p> <p>Ray Jordan<br/>Putnam Insights<br/>ray@putnaminsights.com<br/>(949) 245-5432</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/MDk5YmE2ZGItNTRmMy00Y2JiLWExOTItNDIxODhkZjhjMjc4LTEwMjI2ODU=/tiny/Tonix-Pharmaceuticals-Holding-.png\"/></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TNXP":"Tonix Pharmaceuticals Holding Co","ASR":"å¢Øč„æå„äøåéØęŗåŗ","LU2346227817.USD":"BGF SUSTAINABLE GLOBAL INFRASTRUCTURE \"A2\" (USD) ACC","BK4139":"ēē©ē§ę","BK4588":"ē¢č”","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","BK4583":"ē“ēę¦åæµ","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY \"A\" (USD) ACC","BK4208":"å¤ååå ¬ēØäŗäø","BK4135":"čµäŗ§ē®”ēäøęē®”é¶č”","CNS":"ē§ę©-ęÆčå°ęÆéč","ED":"ē±čæŖēčåēµę°","BK4174":"ęŗåŗęå”","LU0210535034.USD":"ę©ę ¹å¤§éęäøē¾ę“²åŗé","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","FM":"iShareså®ē”MSCIå驱100 ETF","BK4585":"ETF&č”ē„Øå®ęę¦åæµ"},"source_url":"https://www.globenewswire.com/news-release/2024/12/16/2997705/28908/en/Tonix-Pharmaceuticals-Reports-Third-Quarter-2024-Financial-Results-and-Operational-Highlights.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2492611699","content_text":"Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 studies Granted Fast Track Designation by FDA in July 2024 for TNX-102 SL, a centrally-acting, non-opioid analgesic; Fibromyalgia is a common chronic pain condition that affects mostly women Expect FDA decision in December 2024 on TNX-102 SL NDA acceptance for review and 2025 PDUFA date; If FDA-approved in 2025, TNX-102 SL would be the first new drug for fibromyalgia in more than 15 years Presented new data on potential mpox vaccine, TNX-801, in September and October 2024, demonstrating tolerability in immunocompromised animals; Previously reported studies showed a single-dose provided immune protection against a monkeypox challenge Awarded U.S. Department of Defense (DoD) contract for up to $34 million over five years in July 2024 to develop a broad-spectrum antiviral drug; Received first payment from DTRA CHATHAM, N.J., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced financial results for the third quarter ended September 30, 2024, and provided an overview of recent operational highlights. āWith our recent NDA submission to the U.S. Food and Drug Administration (FDA), Tonix is excited about the potential of TNX-102 SL to become the first new drug treatment option in more than 15 years for the roughly 10 million adults in the U.S. suffering from fibromyalgia,ā said Seth Lederman, M.D., Chief Executive Officer of Tonix. āFDA awarded TNX-102 SL Fast Track designation in the third quarter of 2024, which is intended to expedite FDA review of important new drugs to fill unmet needs for serious conditions. We look forward to next steps with FDA. If the NDA filing is accepted in December, we expect a decision on the marketing approval of TNX-102 SL for fibromyalgia in 2025.ā Dr. Lederman continued, āAs we continue to advance key pipeline products through a capital efficient strategy, we are excited to have announced collaborations with world-class institutions to advance the development of TNX-801, a potential mpox vaccine whose single-dose administration and other characteristics align closely with The World Health Organizationās preferred target product profile (TPP) criteria for mpox vaccines. The World Health Organization (WHO) previously announced the growing number of mpox cases constitutes a public health emergency of international concern (PHEIC), with clade 1b mpox strains now detected in 16 countries in Africa as well as in Sweden, Thailand, Singapore, India, England and Germany.ā Key Product Candidates* -- Recent Highlights Central Nervous System (CNS) Pipeline TNX-102 SL (cyclobenzaprine HCl sublingual tablets): 5.6 mg, once-daily at bedtime small molecule for the management of fibromyalgia (FM) ā a centrally-acting, non-opioid analgesic. In October 2024, Tonix announced submission of the TNX-102 SL New Drug Application (NDA) for fibromyalgia to the FDA. The submission was based upon two Phase 3 studies of TNX-102 SL in fibromyalgia that showed statically significant reduction in the chronic, widespread pain associated with fibromyalgia. If approved by the FDA, TNX-102 SL would be the first member of a new class of analgesic drugs for fibromyalgia and the first new drug available for treating fibromyalgia in more than 15 years. Fibromyalgia affects more than 10 million adults in the U.S., most of whom are women.In September 2024, at the 11th Global Conference on Pharmaceutics and Novel Drug Delivery Systems (PDDS 2024), the Company announced data highlighting the proprietary formulation technology and pharmacokinetic properties of TNX-102 SL, including composition and methods patents based on the proprietary eutectic1 formulation of TNX-102 SL that are expected to provide market exclusivity until at least 2034 in the U.S., EU, Japan, China and other jurisdictions. The eutectic protects cyclobenzaprine HCl from interacting with the basifying agent that is also part of the formulation and required for efficient transmucosal absorption. The formulation of TNX-102 SL was designed specifically for sublingual administration and transmucosal absorption for bedtime dosing to target disturbed sleep, improve pain and other fibromyalgia symptoms, while reducing the risk of daytime somnolence.In August 2024, at both the DoDās 2024 Military Health System Research Symposium (MHSRS), and at the International Association for the Study of Painās (IASPās) 2024 World Congress on Pain, Tonix announced additional data and analyses of TNX-102 SL for the management of fibromyalgia. TNX-102 SL had met the pre-specified primary endpoint in the Phase 3 RESILIENT study, significantly reducing daily pain compared to placebo (p-value=0.00005) in participants with fibromyalgia while demonstrating broad syndromal benefits with statistically significant improvement in all six pre-specified key secondary endpoints, including those related to improving sleep quality, reducing fatigue, and improving patient global ratings and overall fibromyalgia symptoms and function. TNX-102 SL was well tolerated with an adverse event profile comparable to prior studies and no new safety signals were observed.In July 2024, Tonix noted that, based on the new definition of Long COVID by the U.S. National Academies of Sciences, Engineering and Medicine (NASEM), fibromyalgia is a ādiagnosable conditionā in people suffering from Long COVID. The Company believes that diagnosing fibromyalgia in Long COVID patients will increase the potential market for TNX-102 SL following approval as compared to market estimates from before the COVID-19 pandemic. TNX-102 SL for the treatment of acute stress reaction (ASR) and acute stress disorder (ASD), and prophylaxis against development of posttraumatic stress disorder (PTSD) In August 2024 at the DoDās MHSRS conference, the Company presented clinical data and rationale supporting the potential for TNX-102 SL to be studied for the treatment of ASR and prevention of PTSD. Prior studies showed that treatment with TNX-102 SL showed effects on sleep and PTSD symptoms in PTSD patients at two and four weeks1. This supportive data on the effects of TNX-102 SL on reducing PTSD symptoms suggest early intervention immediately after trauma using TNX-102 SL has the potential to reduce ASR/ASD symptoms which are similar to those of PTSD2,3. Data from these trials support testing of TNX-102 SL within 24 hours of index trauma for effects on ASR symptoms and the subsequent incidence of PTSD.The DoD-funded Optimizing Acute Stress Reaction Interventions (OASIS) trial will be conducted by the University of North Carolina under an investigator-initiated investigational new drug (IND) application. The OASIS trial will examine the safety and efficacy of TNX-102 SL to reduce adverse posttraumatic neuropsychiatric sequelae among patients in the emergency department (ED) after a motor vehicle collision. Fourteen days of bedtime TNX-102 SL will be dosed and tested in the immediate aftermath of motor vehicle collision. The study will test the potential for TNX-102 SL to target trauma-related sleep disturbance and its ability to facilitate recovery from ASR and to prevent PTSD. The results may ultimately provide military personnel with a new treatment option that, when administered in the early aftermath of a traumatic event to individuals with ASR symptoms, improves warfighter function. TNX-1300 (recombinant double mutant cocaine esterase): biologic for life-threatening cocaine intoxication Tonix announced the first patient in the Phase 2 CATALYST study of TNX-1300 for the treatment of cocaine intoxication was enrolled in August 2024. CATALYST is a Phase 2 single-blind, placebo-controlled, proof-of-concept study in patients presenting to the emergency department. Topline results are expected in the first half of 2025.The National Institutes of Health (NIH)ās National Institute of Drug Abuse (NIDA) previously awarded Tonix a Cooperative Agreement grant for approximately $5 million from to support development of TNX-1300.TNX-1300 has been granted Breakthrough Therapy designation by the FDA. Infectious Disease Pipeline TNX-801 (recombinant horsepox virus, live vaccine): potential vaccine to protect against mpox disease and smallpox. In September 2024, at the DoDās MHSRS conference and in October 2024 at the World Vaccine Congress in Barcelona, Spain, Tonix presented new data on potential mpox vaccine, TNX-801, demonstrating tolerability and no evidence of spreading to blood or tissues, even at high doses, in immunocompromised animals. TNX-801 is an attenuated live-virus vaccine based on synthesized horsepox that has been shown to provide single-dose immune protection against a monkeypox challenge. After a single-dose vaccination, TNX-801 prevented clinical disease and lesions, and also decreased shedding in the mouth and lungs of non-human primates after a lethal challenge with Clade Ia monkeypox. These findings are consistent with TNX-801 inducing mucosal immunity and suggest TNX-801 has the ability to block forward transmission.In August 2024, the WHO determined that the upsurge of mpox in a growing number of countries in Africa constitutes a public health emergency of international concern (PHEIC), the second such declaration in the past two years in response to transmission of the virus. Mpox cases of the new clade 1b mpox have since also been detected in Sweden, Thailand, Singapore, India, Germany and England.In September 2024, the Company announced that the WHOās preferred TPP aligns with the characteristics of TNX-801. Key elements of the WHO draft TPP include single-dose, durable protection, administration without special equipment, and stability at ambient temperature. Other potential beneficial characteristics include the ability to limit forward transmission, use in case-contact vaccination strategies and suitability for use in immunocompromised individuals. Footnotes: The TNX-102 SL eutectic is a composition of matter based on co-penetration of cyclobenzaprine HCl and mannitol crystals and protected by 5 issued U.S patents: Nos. 9,636,408; 9,956,188; 10,117,936; 10,864,175; 11,839,594; 9,918,948; 11,826,321.Sullivan GM, et al. Randomized clinical trial of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related PTSD and the role of sleep quality in treatment response. Psychiatry Res. 2021 Jul;301:113974.Parmenter ME, et al. A phase 3, randomized, placebo-controlled, trial to evaluate the efficacy and safety of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related posttraumatic stress disorder. Psychiatry Res. 2024 (In Press). https://doi.org/10.1016/j.psychres.2024.115764 Corporate and Partnerships ā Recent Highlights In November 2024, the Company announced that it has entered into a sponsored research agreement with the Kenya Medical Research Institute (KEMRI) to design, plan and seek regulatory approval for a Phase I clinical study in Kenya to test the safety, tolerability, and immunogenicity of TNX-801 (horsepox, live virus) as a vaccine to prevent mpox and smallpox. Tonix is expected be the sponsor and KEMRI is expected to lead the execution of the proposed clinical trial.In October 2024, the Company announced it entered into an artificial intelligence and machine learning drug discovery collaboration with X-Chem, Inc., a leader in small molecule drug discovery, to accelerate the development of small molecules as orally available host-targeted broad-spectrum medical countermeasures. Tonixās TNX-4200 antiviral program focuses on the development of oral CD45 phosphatase inhibitors, with broad-spectrum activity against a range of viral families.In September 2024, Tonix announced the appointment of Thomas Englese as its new Executive Vice President, Commercial Operations. Mr. Englese brings significant leadership to Tonix across several functions, including commercial operations, sales and marketing, and launching and managing major brands through all stages of commercialization.Ā Ā In August 2024, the Company announced a collaboration with Bilthoven Biologics (Bbio) to develop GMP manufacturing processes for TNX-801 as a potential mpox vaccine. Bbio is part of the worldās largest vaccine manufacturer, the Cyrus Poonawalla Group, which also includes the Serum Institute of India.Ā Ā In July 2024, Tonix announced it had been awarded a DoD contract with a potential for up to $34 million over five years by DoDās Defense Threat Reduction Agency (DTRA). The objective of the contract is to develop small molecule broad-spectrum antiviral agents for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonixās program will focus on optimization and development of its TNX-4200 program, to develop an orally available CD45 antagonist, with broad-spectrum efficacy against a range of viral families through preclinical evaluation. The program is expected to establish physicochemical properties, pharmacokinetics, and safety attributes to support an IIND submission and to fund a first-in-human Phase 1 clinical study. Marketed Products ā Recent Highlights In September 2024, Tonix announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 12,097,183 to the Company, claiming use of a pre-filled autoinjector comprising a composition of ZembraceĀ® SymTouchĀ® for treating migraines via subcutaneous administration. This patent, excluding possible patent term extensions, is expected to fortify protection and market exclusivity into 2036.Tonix announced that the USPTO issued U.S. Patent No. 12,090,139 to the Company, claiming a pharmaceutical composition, a method of treating migraine via intranasal administration, and an intranasal delivery system for TosymraĀ®. This patent is expected to fortify protection and market exclusivity into 2030. Tonix Medicines launched a national educational campaign focusing on the link between migraine, gastroparesis, and the need for non-oral acute migraine therapies. Tonix Medicines is the only manufacturer with both a branded injectable and nasal spray indicated for the acute treatment of migraine with or without aura in adults. Financial - Recent Highlight As of September 30, 2024, Tonix had approximately $28.2 million of cash and cash equivalents, compared to approximately $24.9 million as of December 31, 2023. Additionally, Tonix had inventory totaling approximately $7.9 million as of September 30, 2024. Net cash used in operations was approximately $46.3 million for the nine months ended September 30, 2024, compared to approximately $79.7 million for the same period in 2023. Cash used in investing activities for the nine months ended September 30, 2024 was approximately $117,000 compared to $28.6 million for the same period in 2023. In July 2024, Tonix received net proceeds of approximately $3.5 million in a securities offering with certain institutional and retail investors. Additionally, during the three months ended September 30, 2024, Tonix sold approximately 134.5 million shares of common stock under the 2024 ATM Sales Agreement for net proceeds of approximately $41.8 million. Third Quarter 2024 Financial Results Net product revenue for the third quarter 2024 was approximately $2.8 million. Net product revenue consisted of combined net sales of ZembraceĀ® SymTouchĀ® and TosymraĀ®, which were acquired from Upsher-Smith Laboratories, LLC on June 30, 2023. Cost of sales for the third quarter 2024 was approximately $1.6 million. During the three months ended September 30, 2024, Tonix received its first payment from DTRA as part of its previously announced award from DTRA for up to $34 million over five years. Research and development expenses for the third quarter 2024 were approximately $9.1 million, compared to $21.0 million for the same period in 2023. This decrease is predominantly due to lower clinical, non-clinical and manufacturing expenses aligned with the Companyās capital efficient strategy. Selling, general and administrative expenses for the third quarter 2024 were approximately $7.7 million, compared to $8.7 million for the same period in 2023. The decrease was primarily due to lower employee-related expenses, transactional services and sales and marketing expenses partially offset by an increase in professional fees. Net loss available to common stockholders was approximately $14.2 million, or $0.23 per share, basic and diluted, for the third quarter 2024, compared to net loss available to common stockholders of $28.0 million, or $38.63 per share, basic and diluted, for the same period in 2023. The basic and diluted weighted average common shares outstanding for the third quarter 2024 was 62,122,283 compared to 724,190 shares for the same period in 2023. Tonix Pharmaceuticals Holding Corp.*Tonix is a fully-integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges. Tonixās development portfolio is focused on central nervous system (CNS) disorders. Tonixās priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia. The FDA has granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. We expect an FDA decision on the acceptance of the NDA for review and a PDUFA date in December and if accepted, a decision on NDA approval in 2025. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonixās CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has FDA Breakthrough Therapy designation and its development is supported by a grant from the U.S. National Institute of Drug Abuse and Addiction. Tonixās immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease, including TNX-2900 for Prader-Willi syndrome, and infectious disease, including a vaccine for mpox, TNX-801. Tonix recently announced a contract with the U.S. DoDās Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, MD. Tonix Medicines, our commercial subsidiary, markets ZembraceĀ® SymTouchĀ® (sumatriptan injection) 3 mg and TosymraĀ® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults. * Tonixās product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners. This press release and further information about Tonix can be found at www.tonixpharma.com. Forward Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as āanticipate,ā ābelieve,ā āforecast,ā āestimate,ā āexpect,ā and āintend,ā among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the āSECā) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof. TONIX PHARMACEUTICALS HOLDING CORP.Ā CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In Thousands, Except Share and Per Share Amounts)(unaudited)Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Three Months EndedSeptember 30,Ā Ā Nine Months EndedSeptember 30,Ā Ā Ā Ā 2024Ā Ā 2023Ā Ā 2024Ā Ā 2023Ā REVENUE:Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Product revenue, netĀ Ā $2,822Ā Ā $3,989Ā Ā $7,512Ā Ā $3,989Ā COSTS AND EXPENSES:Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Cost of revenueĀ Ā Ā 1,555Ā Ā Ā 2,374Ā Ā Ā 6,582Ā Ā Ā 2,374Ā Research and developmentĀ Ā Ā 9,114Ā Ā Ā 21,050Ā Ā Ā 31,675Ā Ā Ā 69,535Ā Selling, general and administrativeĀ Ā Ā 7,707Ā Ā Ā 8,712Ā Ā Ā 24,519Ā Ā Ā 23,131Ā Asset impairment chargesĀ Ā Ā āĀ Ā Ā āĀ Ā Ā 58,957Ā Ā Ā āĀ Ā Ā Ā Ā 18,376Ā Ā Ā 32,136Ā Ā Ā 121,733Ā Ā Ā 95,040Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Operating lossĀ Ā Ā (15,554)Ā Ā (28,147)Ā Ā (114,221)Ā Ā (91,051)Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Grant incomeĀ Ā Ā 1,668Ā Ā Ā āĀ Ā Ā 1,668Ā Ā Ā āĀ Gain on change in fair value of warrant liabilitiesĀ Ā Ā āĀ Ā Ā āĀ Ā Ā 6,150Ā Ā Ā āĀ Other (expense) income, netĀ Ā Ā (327)Ā Ā 172Ā Ā Ā (1,525)Ā Ā 1,715Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Net loss available to common stockholdersĀ Ā $(14,213)Ā $(27,975)Ā $(107,928)Ā $(89,336)Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Net loss per common share, basic and dilutedĀ Ā $(0.23)Ā $(38.63)Ā $(4.66)Ā $(143.47)Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Weighted average common shares outstanding, basic and dilutedĀ Ā Ā 62,122,283Ā Ā Ā 724,190Ā Ā Ā 23,136,172Ā Ā Ā 622,684Ā Ā TONIX PHARMACEUTICALS HOLDING CORP.CONDENSED CONSOLIDATED BALANCE SHEETS (In Thousands)(Unaudited)Ā Ā September 30, 2024Ā December 31, 20231AssetsĀ Ā Ā Ā Ā Cash and cash equivalents$Ā Ā 28,233Ā Ā $Ā Ā 24,948Ā Accounts Receivable, net4,013Ā Ā -Ā Inventory7,931Ā Ā 13,639Ā Prepaid expenses and other10,366Ā Ā 9,181Ā Total current assets50,543Ā Ā 47,768Ā Other non-current assets44,446Ā Ā 106,689Ā Total assets$Ā Ā 94,989Ā Ā $Ā Ā 154,457Ā Ā Ā Ā Ā Ā Ā Liabilities and stockholders' equityĀ Ā Ā Ā Ā Total liabilities$Ā Ā 20,778Ā Ā $Ā Ā 48,932Ā Stockholders' equity74,211Ā Ā 105,525Ā Total liabilities and stockholders' equity$Ā Ā 94,989Ā Ā $Ā Ā 154,457Ā Ā 1The condensed consolidated balance sheet for the year ended December 31, 2023 has been derived from the audited financial statements but do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.Ā Investor Contact Jessica MorrisTonix Pharmaceuticalsinvestor.relations@tonixpharma.com (862) 904-8182 Peter VozzoICR Healthcarepeter.vozzo@westwicke.com (443) 213-0505 Media Contact Ray JordanPutnam Insightsray@putnaminsights.com(949) 245-5432","news_type":1},"isVote":1,"tweetType":1,"viewCount":405,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4141429963588842","authorId":"4141429963588842","name":"TigerGPT","avatar":"https://community-static.tradeup.com/news/5b82af1deb17dfa8f94b4741b9ea2738","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"4141429963588842","idStr":"4141429963588842"},"content":"Based on the information available, it seems that there is no specific analysis or valuation data for Tonix Pharmaceuticals (TNXP) at the moment. However, there are some recent news articles related to the company: Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights: This article discusses Tonix Pharmaceuticals submitting a New Drug Application (NDA) to the FDA for TNX-102 SL for fibromyalgia. The company was also granted Fast Track Designation by the FDA for TNX-102 SL. NDA Filed for TNX-102 SL in Fibromyalgia: This article highlights the filing of the NDA for TNX-102 SL in fibromyalgia by Tonix Pharmaceuticals. Tonix Pharmaceuticals appoints Raudabaugh, Gould as VPs: Tonix Pharmaceuticals announced the expansion of its leadership team to support the launch of TNX-102 SL for the management of fibromyalgia. Tonix Pharmaceuticals to Participate in the NobleCon20 Investor Conference: This article mentions Tonix Pharmaceuticals' participation in the NobleCon20 Investor Conference. Please note that the news articles provided are for informational purposes only and should not be considered as investment advice or a recommendation to hold Tonix Pharmaceuticals (TNXP) for the long term. Remember to conduct thorough research and analysis before making any investment decisions. If you require more up-to-date and comprehensive information, I recommend reviewing the stock quote page or consulting with a professional financial advisor.","text":"Based on the information available, it seems that there is no specific analysis or valuation data for Tonix Pharmaceuticals (TNXP) at the moment. However, there are some recent news articles related to the company: Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights: This article discusses Tonix Pharmaceuticals submitting a New Drug Application (NDA) to the FDA for TNX-102 SL for fibromyalgia. The company was also granted Fast Track Designation by the FDA for TNX-102 SL. NDA Filed for TNX-102 SL in Fibromyalgia: This article highlights the filing of the NDA for TNX-102 SL in fibromyalgia by Tonix Pharmaceuticals. Tonix Pharmaceuticals appoints Raudabaugh, Gould as VPs: Tonix Pharmaceuticals announced the expansion of its leadership team to support the launch of TNX-102 SL for the management of fibromyalgia. Tonix Pharmaceuticals to Participate in the NobleCon20 Investor Conference: This article mentions Tonix Pharmaceuticals' participation in the NobleCon20 Investor Conference. Please note that the news articles provided are for informational purposes only and should not be considered as investment advice or a recommendation to hold Tonix Pharmaceuticals (TNXP) for the long term. Remember to conduct thorough research and analysis before making any investment decisions. If you require more up-to-date and comprehensive information, I recommend reviewing the stock quote page or consulting with a professional financial advisor.","html":"Based on the information available, it seems that there is no specific analysis or valuation data for Tonix Pharmaceuticals (TNXP) at the moment. However, there are some recent news articles related to the company: Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights: This article discusses Tonix Pharmaceuticals submitting a New Drug Application (NDA) to the FDA for TNX-102 SL for fibromyalgia. The company was also granted Fast Track Designation by the FDA for TNX-102 SL. NDA Filed for TNX-102 SL in Fibromyalgia: This article highlights the filing of the NDA for TNX-102 SL in fibromyalgia by Tonix Pharmaceuticals. Tonix Pharmaceuticals appoints Raudabaugh, Gould as VPs: Tonix Pharmaceuticals announced the expansion of its leadership team to support the launch of TNX-102 SL for the management of fibromyalgia. Tonix Pharmaceuticals to Participate in the NobleCon20 Investor Conference: This article mentions Tonix Pharmaceuticals' participation in the NobleCon20 Investor Conference. Please note that the news articles provided are for informational purposes only and should not be considered as investment advice or a recommendation to hold Tonix Pharmaceuticals (TNXP) for the long term. Remember to conduct thorough research and analysis before making any investment decisions. If you require more up-to-date and comprehensive information, I recommend reviewing the stock quote page or consulting with a professional financial advisor."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":382168804778120,"gmtCreate":1734334342051,"gmtModify":1734334345487,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4156648821928502","idStr":"4156648821928502"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/382168804778120","repostId":"382184588726600","repostType":1,"repost":{"id":382184588726600,"gmtCreate":1734282328563,"gmtModify":1734328202421,"author":{"id":"4171900329979952","authorId":"4171900329979952","name":"Barcode","avatar":"https://community-static.tradeup.com/news/6688d8fb4c2a255e3b901e79755e56df","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4171900329979952","idStr":"4171900329979952"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/MARA\">$MARA Holdings(MARA)$</a> <a href=\"https://ttm.financial/S/RIOT\">$Riot Platforms(RIOT)$</a> <a href=\"https://ttm.financial/S/WULF\">$TeraWulf Inc.(WULF)$</a> <a href=\"https://ttm.financial/S/CLSK\">$CleanSpark, Inc.(CLSK)$</a> <a href=\"https://ttm.financial/S/HUT\">$Hut 8 Mining Corp(HUT)$</a> $IREN šŗš š ±ļø U Å Å Å $ Ņ¤ šŗ š§šŗļøšÆāļø Miner Fib Levels Mapped: Follow the BC BTC Miner Map Cycle to Peak Profits! šš°š§šŗļø š„ $MARA: š Key levels: $22.10, $23.18, $24.57 ~ š„š¤ knock out that $24.57 level and we move again šŗš. Handle forming on the 4hr chart. ā” $RIOT: š Key levels: $13.15, $13.94, $14.29-$14.54. Inverse Head & Shoulders (IHS) set up. š $WULF: I love this set-up! Harmonic potential on a C-to-D leg. š Key levels: $8.90 then $10,","listText":"<a href=\"https://ttm.financial/S/MARA\">$MARA Holdings(MARA)$</a> <a href=\"https://ttm.financial/S/RIOT\">$Riot Platforms(RIOT)$</a> <a href=\"https://ttm.financial/S/WULF\">$TeraWulf Inc.(WULF)$</a> <a href=\"https://ttm.financial/S/CLSK\">$CleanSpark, Inc.(CLSK)$</a> <a href=\"https://ttm.financial/S/HUT\">$Hut 8 Mining Corp(HUT)$</a> $IREN šŗš š ±ļø U Å Å Å $ Ņ¤ šŗ š§šŗļøšÆāļø Miner Fib Levels Mapped: Follow the BC BTC Miner Map Cycle to Peak Profits! šš°š§šŗļø š„ $MARA: š Key levels: $22.10, $23.18, $24.57 ~ š„š¤ knock out that $24.57 level and we move again šŗš. Handle forming on the 4hr chart. ā” $RIOT: š Key levels: $13.15, $13.94, $14.29-$14.54. Inverse Head & Shoulders (IHS) set up. š $WULF: I love this set-up! Harmonic potential on a C-to-D leg. š Key levels: $8.90 then $10,","text":"$MARA Holdings(MARA)$ $Riot Platforms(RIOT)$ $TeraWulf Inc.(WULF)$ $CleanSpark, Inc.(CLSK)$ $Hut 8 Mining Corp(HUT)$ $IREN šŗš š ±ļø U Å Å Å $ Ņ¤ šŗ š§šŗļøšÆāļø Miner Fib Levels Mapped: Follow the BC BTC Miner Map Cycle to Peak Profits! šš°š§šŗļø š„ $MARA: š Key levels: $22.10, $23.18, $24.57 ~ š„š¤ knock out that $24.57 level and we move again šŗš. Handle forming on the 4hr chart. ā” $RIOT: š Key levels: $13.15, $13.94, $14.29-$14.54. Inverse Head & Shoulders (IHS) set up. š $WULF: I love this set-up! Harmonic potential on a C-to-D leg. š Key levels: $8.90 then $10,","images":[{"img":"https://community-static.tradeup.com/news/fc3b1d882744e5b5aa4e5cfb695d8b1e","width":"1269","height":"938"},{"img":"https://community-static.tradeup.com/news/37b632f4937a284d8adc93f2a664b16b","width":"893","height":"796"},{"img":"https://community-static.tradeup.com/news/750d19511e5fb0569fe41a136dea5068","width":"1263","height":"931"}],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/382184588726600","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":99,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":382149899346088,"gmtCreate":1734329728350,"gmtModify":1734329732930,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4156648821928502","idStr":"4156648821928502"},"themes":[],"htmlText":"Replying to <a href=\"https://ttm.financial/U/4178332581629092\">@Boybabyrage</a>:Yes bro we have made strong decisions. Cheers bro.. Wish you wealthy trading//<a href=\"https://ttm.financial/U/4178332581629092\">@Boybabyrage</a>:hahaha good that we hold back then , cheers bro","listText":"Replying to <a href=\"https://ttm.financial/U/4178332581629092\">@Boybabyrage</a>:Yes bro we have made strong decisions. Cheers bro.. Wish you wealthy trading//<a href=\"https://ttm.financial/U/4178332581629092\">@Boybabyrage</a>:hahaha good that we hold back then , cheers bro","text":"Replying to @Boybabyrage:Yes bro we have made strong decisions. Cheers bro.. Wish you wealthy trading//@Boybabyrage:hahaha good that we hold back then , cheers bro","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/382149899346088","repostId":"382306116657496","repostType":1,"repost":{"id":382306116657496,"gmtCreate":1734313280872,"gmtModify":1734314437962,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4156648821928502","idStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> go go <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a> <a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> ","listText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> go go <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a> <a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> ","text":"$Tonix Pharmaceuticals(TNXP)$ go go @TigerGPT $Tonix Pharmaceuticals(TNXP)$","images":[{"img":"https://community-static.tradeup.com/news/55dff79059585e883aa3822ef60623d7","width":"1068","height":"1112"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/382306116657496","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":53,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":382306116657496,"gmtCreate":1734313280872,"gmtModify":1734314437962,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4156648821928502","idStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> go go <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a> <a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> ","listText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> go go <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a> <a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> ","text":"$Tonix Pharmaceuticals(TNXP)$ go go @TigerGPT $Tonix Pharmaceuticals(TNXP)$","images":[{"img":"https://community-static.tradeup.com/news/55dff79059585e883aa3822ef60623d7","width":"1068","height":"1112"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":75,"commentSize":5,"repostSize":190,"link":"https://ttm.financial/post/382306116657496","isVote":1,"tweetType":1,"viewCount":3965,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/5b59a07cca9804884b312ca8a7ac871d","crmLevel":8,"crmLevelSwitch":1,"authorIdStr":"4178332581629092","idStr":"4178332581629092"},"content":"hahaha good that we hold back then , cheers bro","text":"hahaha good that we hold back then , cheers bro","html":"hahaha good that we hold back then , cheers bro"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":380534752395336,"gmtCreate":1733955039574,"gmtModify":1733974294402,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4156648821928502","idStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TBLA\">$Taboola Com Ltd(TBLA)$</a> <a href=\"https://ttm.financial/S/TBLA\">$Taboola Com Ltd(TBLA)$</a> still not selling <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a> ","listText":"<a href=\"https://ttm.financial/S/TBLA\">$Taboola Com Ltd(TBLA)$</a> <a href=\"https://ttm.financial/S/TBLA\">$Taboola Com Ltd(TBLA)$</a> still not selling <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a> ","text":"$Taboola Com Ltd(TBLA)$ $Taboola Com Ltd(TBLA)$ still not selling @Barcode @TigerGPT","images":[{"img":"https://community-static.tradeup.com/news/2ee79339e0fd3e4e5690e804a861d5f0","width":"327","height":"545"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":13,"commentSize":1,"repostSize":1,"link":"https://ttm.financial/post/380534752395336","isVote":1,"tweetType":1,"viewCount":166,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4141429963588842","authorId":"4141429963588842","name":"TigerGPT","avatar":"https://community-static.tradeup.com/news/5b82af1deb17dfa8f94b4741b9ea2738","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"4141429963588842","idStr":"4141429963588842"},"content":"Based on the latest information available for Taboola Com Ltd (TBLA): Stock Name: Taboola Com Ltd Stock Code: TBLA Stock Price: $4.26 (USD) Yesterday's Closing Price: $4.08 (USD) 52-Week High: $5.00 (USD) 52-Week Low: $2.87 (USD) Market Capitalization: $1.43 billion (USD) Circulating Market Cap: $769.68 million (USD) Total Share Capital: 336.21 million Float Share Capital: 180.68 million Price-to-Earnings Ratio (TTM): -44.277 Price-to-Sales Ratio (TTM): 0.85 Price-to-Book Ratio: 1.42 Earnings per Share (LYR): -$0.24 Earnings per Share (TTM): -$0.10 Return on Assets (ROA): -0.46% Return on Equity (ROE): -3.19% Trading Volume: 2.43 million shares Trading Value: $10.29 million (USD) Volume Ratio: 1.39 Analyst Recommendations: 1 recommend 5 buy 1 hold Analyst Target Price: Mean: $5.33 (USD) Low: $5.00 (USD) High: $6.00 (USD) Recent News: Taboola Signs New Content Recommendations Deal With Future, Extending Partnership Into 12th Year Read more Taboola.com Signs New 3-Year Deal With WeatherBug Read more Taboola and WeatherBug Announce New, Exclusive Multi-Year Deal Read more Please note that the stock information provided is for reference purposes only and does not constitute investment advice. It is recommended to conduct thorough research and analysis before making any investment decisions.","text":"Based on the latest information available for Taboola Com Ltd (TBLA): Stock Name: Taboola Com Ltd Stock Code: TBLA Stock Price: $4.26 (USD) Yesterday's Closing Price: $4.08 (USD) 52-Week High: $5.00 (USD) 52-Week Low: $2.87 (USD) Market Capitalization: $1.43 billion (USD) Circulating Market Cap: $769.68 million (USD) Total Share Capital: 336.21 million Float Share Capital: 180.68 million Price-to-Earnings Ratio (TTM): -44.277 Price-to-Sales Ratio (TTM): 0.85 Price-to-Book Ratio: 1.42 Earnings per Share (LYR): -$0.24 Earnings per Share (TTM): -$0.10 Return on Assets (ROA): -0.46% Return on Equity (ROE): -3.19% Trading Volume: 2.43 million shares Trading Value: $10.29 million (USD) Volume Ratio: 1.39 Analyst Recommendations: 1 recommend 5 buy 1 hold Analyst Target Price: Mean: $5.33 (USD) Low: $5.00 (USD) High: $6.00 (USD) Recent News: Taboola Signs New Content Recommendations Deal With Future, Extending Partnership Into 12th Year Read more Taboola.com Signs New 3-Year Deal With WeatherBug Read more Taboola and WeatherBug Announce New, Exclusive Multi-Year Deal Read more Please note that the stock information provided is for reference purposes only and does not constitute investment advice. It is recommended to conduct thorough research and analysis before making any investment decisions.","html":"Based on the latest information available for Taboola Com Ltd (TBLA): Stock Name: Taboola Com Ltd Stock Code: TBLA Stock Price: $4.26 (USD) Yesterday's Closing Price: $4.08 (USD) 52-Week High: $5.00 (USD) 52-Week Low: $2.87 (USD) Market Capitalization: $1.43 billion (USD) Circulating Market Cap: $769.68 million (USD) Total Share Capital: 336.21 million Float Share Capital: 180.68 million Price-to-Earnings Ratio (TTM): -44.277 Price-to-Sales Ratio (TTM): 0.85 Price-to-Book Ratio: 1.42 Earnings per Share (LYR): -$0.24 Earnings per Share (TTM): -$0.10 Return on Assets (ROA): -0.46% Return on Equity (ROE): -3.19% Trading Volume: 2.43 million shares Trading Value: $10.29 million (USD) Volume Ratio: 1.39 Analyst Recommendations: 1 recommend 5 buy 1 hold Analyst Target Price: Mean: $5.33 (USD) Low: $5.00 (USD) High: $6.00 (USD) Recent News: Taboola Signs New Content Recommendations Deal With Future, Extending Partnership Into 12th Year Read more Taboola.com Signs New 3-Year Deal With WeatherBug Read more Taboola and WeatherBug Announce New, Exclusive Multi-Year Deal Read more Please note that the stock information provided is for reference purposes only and does not constitute investment advice. It is recommended to conduct thorough research and analysis before making any investment decisions."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":380481956446488,"gmtCreate":1733927670736,"gmtModify":1733927862552,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4156648821928502","idStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/GOEV\">$Canoo Inc.(GOEV)$ </a><v-v data-views=\"0\"></v-v> Shit big shit<a href=\"https://ttm.financial/S/GOEV\">$Canoo Inc.(GOEV)$ </a> <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> boss any luck here <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a> ","listText":"<a href=\"https://ttm.financial/S/GOEV\">$Canoo Inc.(GOEV)$ </a><v-v data-views=\"0\"></v-v> Shit big shit<a href=\"https://ttm.financial/S/GOEV\">$Canoo Inc.(GOEV)$ </a> <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> boss any luck here <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a> ","text":"$Canoo Inc.(GOEV)$ Shit big shit$Canoo Inc.(GOEV)$ @Barcode boss any luck here @TigerGPT","images":[{"img":"https://community-static.tradeup.com/news/f36fb756dd117ca9933ef74fa066a6eb","width":"327","height":"545"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/380481956446488","isVote":1,"tweetType":1,"viewCount":236,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4141429963588842","authorId":"4141429963588842","name":"TigerGPT","avatar":"https://community-static.tradeup.com/news/5b82af1deb17dfa8f94b4741b9ea2738","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"4141429963588842","idStr":"4141429963588842"},"content":"Canoo Inc. (GOEV) has experienced a recent movement in its stock price. After analyzing the available news, we found an article discussing the Wall Street analysts' views on investing in Canoo. The article indicates that Canoo currently has an average brokerage recommendation (ABR) of 1.57, which falls between Strong Buy and Buy. Out of the seven recommendations that make up the ABR, five are Strong Buy, representing 71.4% of all recommendations. It's worth noting that brokerage firms may have a vested interest in the stocks they cover, which can result in a positive bias in their analysts' ratings. You can read the full article here. Please keep in mind that the movement in Canoo's stock price may also be influenced by factors such as stock capital flow. If there are no significant news articles available or the news articles do not directly explain the stock movement, stock capital flow could be a potential reason. Remember that stock movements can be affected by various factors and can change rapidly. It is important to conduct thorough research and analysis before making any investment decisions. Note: The information provided is for reference purposes only and does not constitute investment advice.","text":"Canoo Inc. (GOEV) has experienced a recent movement in its stock price. After analyzing the available news, we found an article discussing the Wall Street analysts' views on investing in Canoo. The article indicates that Canoo currently has an average brokerage recommendation (ABR) of 1.57, which falls between Strong Buy and Buy. Out of the seven recommendations that make up the ABR, five are Strong Buy, representing 71.4% of all recommendations. It's worth noting that brokerage firms may have a vested interest in the stocks they cover, which can result in a positive bias in their analysts' ratings. You can read the full article here. Please keep in mind that the movement in Canoo's stock price may also be influenced by factors such as stock capital flow. If there are no significant news articles available or the news articles do not directly explain the stock movement, stock capital flow could be a potential reason. Remember that stock movements can be affected by various factors and can change rapidly. It is important to conduct thorough research and analysis before making any investment decisions. Note: The information provided is for reference purposes only and does not constitute investment advice.","html":"Canoo Inc. (GOEV) has experienced a recent movement in its stock price. After analyzing the available news, we found an article discussing the Wall Street analysts' views on investing in Canoo. The article indicates that Canoo currently has an average brokerage recommendation (ABR) of 1.57, which falls between Strong Buy and Buy. Out of the seven recommendations that make up the ABR, five are Strong Buy, representing 71.4% of all recommendations. It's worth noting that brokerage firms may have a vested interest in the stocks they cover, which can result in a positive bias in their analysts' ratings. You can read the full article here. Please keep in mind that the movement in Canoo's stock price may also be influenced by factors such as stock capital flow. If there are no significant news articles available or the news articles do not directly explain the stock movement, stock capital flow could be a potential reason. Remember that stock movements can be affected by various factors and can change rapidly. It is important to conduct thorough research and analysis before making any investment decisions. Note: The information provided is for reference purposes only and does not constitute investment advice."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":379716235325704,"gmtCreate":1733730883980,"gmtModify":1733730887359,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4156648821928502","idStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$ </a> early Christmas ","listText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$ </a> early Christmas ","text":"$Tiger Brokers(TIGR)$ early Christmas","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/379716235325704","isVote":1,"tweetType":1,"viewCount":105,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":377279086330208,"gmtCreate":1733148304193,"gmtModify":1733148308632,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4156648821928502","idStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/U/4141429963588842\"> @TigerGPT </a>any good news on <a href=\"https://ttm.financial/S/TNXP\"> $Tonix Pharmaceuticals(TNXP)$ </a>","listText":"<a href=\"https://ttm.financial/U/4141429963588842\"> @TigerGPT </a>any good news on <a href=\"https://ttm.financial/S/TNXP\"> $Tonix Pharmaceuticals(TNXP)$ </a>","text":"@TigerGPT any good news on $Tonix Pharmaceuticals(TNXP)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/377279086330208","repostId":"373183558132104","repostType":1,"repost":{"id":373183558132104,"gmtCreate":1732154753974,"gmtModify":1732154758098,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/5b59a07cca9804884b312ca8a7ac871d","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4178332581629092","idStr":"4178332581629092"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> Once the vaccine gets FDA approval, it will be skyrocket ","listText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> Once the vaccine gets FDA approval, it will be skyrocket ","text":"$Tonix Pharmaceuticals(TNXP)$ Once the vaccine gets FDA approval, it will be skyrocket","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/373183558132104","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":280,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4141429963588842","authorId":"4141429963588842","name":"TigerGPT","avatar":"https://community-static.tradeup.com/news/5b82af1deb17dfa8f94b4741b9ea2738","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"4141429963588842","idStr":"4141429963588842"},"content":"Yes, there are some good news articles about Tonix Pharmaceuticals (TNXP). Here are a few of them: Tonix Pharmaceuticals presents data, analyses of TNX-102 SL effects: Tonix Pharmaceuticals presented data in a poster presentation at the ACR Convergence 2024 Annual Meeting, highlighting the effects of TNX-102 SL. Tonix Pharmaceuticals announces publication of study on tolerability of TNX-801: Tonix Pharmaceuticals announced the publication of a paper on the tolerability of TNX-801, a vaccine candidate. Tonix Pharmaceuticals announces peer-reviewed publication in Msphere Journal: Tonix Pharmaceuticals announced a peer-reviewed publication in Msphere Journal, highlighting the tolerability of TNX-801 in immune-compromised animals. Tonix Pharmaceuticals Holding Corp reports results for the quarter ended September 30: Tonix Pharmaceuticals reported quarterly losses that beat analyst consensus estimates. These articles provide insights into the company's research, publications, and financial performance. For more detailed information, you can click on the provided links. Please note that the information provided is for reference purposes only and does not constitute investment advice. Investing in stocks involves risks, and it is essential to conduct thorough research and analysis before making any investment decisions. Let me know if there's anything else I can assist you with!","text":"Yes, there are some good news articles about Tonix Pharmaceuticals (TNXP). Here are a few of them: Tonix Pharmaceuticals presents data, analyses of TNX-102 SL effects: Tonix Pharmaceuticals presented data in a poster presentation at the ACR Convergence 2024 Annual Meeting, highlighting the effects of TNX-102 SL. Tonix Pharmaceuticals announces publication of study on tolerability of TNX-801: Tonix Pharmaceuticals announced the publication of a paper on the tolerability of TNX-801, a vaccine candidate. Tonix Pharmaceuticals announces peer-reviewed publication in Msphere Journal: Tonix Pharmaceuticals announced a peer-reviewed publication in Msphere Journal, highlighting the tolerability of TNX-801 in immune-compromised animals. Tonix Pharmaceuticals Holding Corp reports results for the quarter ended September 30: Tonix Pharmaceuticals reported quarterly losses that beat analyst consensus estimates. These articles provide insights into the company's research, publications, and financial performance. For more detailed information, you can click on the provided links. Please note that the information provided is for reference purposes only and does not constitute investment advice. Investing in stocks involves risks, and it is essential to conduct thorough research and analysis before making any investment decisions. Let me know if there's anything else I can assist you with!","html":"Yes, there are some good news articles about Tonix Pharmaceuticals (TNXP). Here are a few of them: Tonix Pharmaceuticals presents data, analyses of TNX-102 SL effects: Tonix Pharmaceuticals presented data in a poster presentation at the ACR Convergence 2024 Annual Meeting, highlighting the effects of TNX-102 SL. Tonix Pharmaceuticals announces publication of study on tolerability of TNX-801: Tonix Pharmaceuticals announced the publication of a paper on the tolerability of TNX-801, a vaccine candidate. Tonix Pharmaceuticals announces peer-reviewed publication in Msphere Journal: Tonix Pharmaceuticals announced a peer-reviewed publication in Msphere Journal, highlighting the tolerability of TNX-801 in immune-compromised animals. Tonix Pharmaceuticals Holding Corp reports results for the quarter ended September 30: Tonix Pharmaceuticals reported quarterly losses that beat analyst consensus estimates. These articles provide insights into the company's research, publications, and financial performance. For more detailed information, you can click on the provided links. Please note that the information provided is for reference purposes only and does not constitute investment advice. Investing in stocks involves risks, and it is essential to conduct thorough research and analysis before making any investment decisions. Let me know if there's anything else I can assist you with!"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":377323210502448,"gmtCreate":1733148259565,"gmtModify":1733148264006,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4156648821928502","idStr":"4156648821928502"},"themes":[],"htmlText":"Replying to <a href=\"https://ttm.financial/U/4178332581629092\">@Boybabyrage</a>:Thank you.. Wish you wealthy trading.. Cheers//<a href=\"https://ttm.financial/U/4178332581629092\">@Boybabyrage</a>:I read somewhere around Dec 2024 or early 2025","listText":"Replying to <a href=\"https://ttm.financial/U/4178332581629092\">@Boybabyrage</a>:Thank you.. Wish you wealthy trading.. Cheers//<a href=\"https://ttm.financial/U/4178332581629092\">@Boybabyrage</a>:I read somewhere around Dec 2024 or early 2025","text":"Replying to @Boybabyrage:Thank you.. Wish you wealthy trading.. Cheers//@Boybabyrage:I read somewhere around Dec 2024 or early 2025","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/377323210502448","repostId":"373183558132104","repostType":1,"repost":{"id":373183558132104,"gmtCreate":1732154753974,"gmtModify":1732154758098,"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/5b59a07cca9804884b312ca8a7ac871d","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4178332581629092","idStr":"4178332581629092"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> Once the vaccine gets FDA approval, it will be skyrocket ","listText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> Once the vaccine gets FDA approval, it will be skyrocket ","text":"$Tonix Pharmaceuticals(TNXP)$ Once the vaccine gets FDA approval, it will be skyrocket","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/373183558132104","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":79,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":377278350070152,"gmtCreate":1733148127448,"gmtModify":1733148131249,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4156648821928502","idStr":"4156648821928502"},"themes":[],"htmlText":"Boss, I wanted to express my heartfelt gratitude for your patience, thorough analysis, and kindness. Your willingness to assist me without prior acquaintance is truly admirable. I feel privileged to have connected with you. Thank you again, and I wish you continued success, happiness, and prosperity.","listText":"Boss, I wanted to express my heartfelt gratitude for your patience, thorough analysis, and kindness. Your willingness to assist me without prior acquaintance is truly admirable. I feel privileged to have connected with you. Thank you again, and I wish you continued success, happiness, and prosperity.","text":"Boss, I wanted to express my heartfelt gratitude for your patience, thorough analysis, and kindness. Your willingness to assist me without prior acquaintance is truly admirable. I feel privileged to have connected with you. Thank you again, and I wish you continued success, happiness, and prosperity.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/377278350070152","repostId":"377276690907192","repostType":1,"repost":{"id":377276690907192,"gmtCreate":1733147717608,"gmtModify":1733193382954,"author":{"id":"4171900329979952","authorId":"4171900329979952","name":"Barcode","avatar":"https://community-static.tradeup.com/news/6688d8fb4c2a255e3b901e79755e56df","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4171900329979952","idStr":"4171900329979952"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a> <a href=\"https://ttm.financial/U/4156648821928502\">@Kallu</a> Replying to your \"stuck in these stocks\" message mate! Time & Patience for TIGR A higher run into EOY for $ROKU Time & Patience for $ASPN Charts attached for your info. Good luck! Wishing you the best! Happy trading ahead! Cheers BC ššš","listText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a> <a href=\"https://ttm.financial/U/4156648821928502\">@Kallu</a> Replying to your \"stuck in these stocks\" message mate! Time & Patience for TIGR A higher run into EOY for $ROKU Time & Patience for $ASPN Charts attached for your info. Good luck! Wishing you the best! Happy trading ahead! Cheers BC ššš","text":"$Tiger Brokers(TIGR)$ @Kallu Replying to your \"stuck in these stocks\" message mate! Time & Patience for TIGR A higher run into EOY for $ROKU Time & Patience for $ASPN Charts attached for your info. Good luck! Wishing you the best! Happy trading ahead! Cheers BC ššš","images":[{"img":"https://community-static.tradeup.com/news/61b8a309b9b02f6187fb572079ead7b6","width":"1302","height":"909"},{"img":"https://community-static.tradeup.com/news/be418b742d26df3767ea1b2ea0a54cd7","width":"1214","height":"864"},{"img":"https://community-static.tradeup.com/news/1b128d7ca6203959c855f3437149035a","width":"2150","height":"1988"}],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/377276690907192","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":42,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":376632835682624,"gmtCreate":1732970577028,"gmtModify":1732970581741,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4156648821928502","idStr":"4156648821928502"},"themes":[],"htmlText":"Hoping Santa and <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> brings a market. My portfolio's still in the red, but I'm counting on a December rebound.<a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a> <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> ","listText":"Hoping Santa and <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> brings a market. My portfolio's still in the red, but I'm counting on a December rebound.<a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a> <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> ","text":"Hoping Santa and @Barcode brings a market. My portfolio's still in the red, but I'm counting on a December rebound.@TigerGPT @Barcode","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":4,"repostSize":1,"link":"https://ttm.financial/post/376632835682624","isVote":1,"tweetType":1,"viewCount":315,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4171900329979952","authorId":"4171900329979952","name":"Barcode","avatar":"https://community-static.tradeup.com/news/6688d8fb4c2a255e3b901e79755e56df","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"4171900329979952","idStr":"4171900329979952"},"content":"Kia ora Kallu, Kallu! You know Iāve got Santa on speed dial, and Iām already working on getting some festive magic into the market for you! šš No pressure, right? š¤£ By the way, TSLA loves a good Christmas rally, you in? $Direxion Daily TSLA Bull 2X Shares(TSLL)$ šš What stocks are you in? Miners? Hang in there, Decemberās got plenty of potential, and you never know when the market might surprise us with a little extra sparkle. Letās see if we can turn that red into something much more cheerful ššš","text":"Kia ora Kallu, Kallu! You know Iāve got Santa on speed dial, and Iām already working on getting some festive magic into the market for you! šš No pressure, right? š¤£ By the way, TSLA loves a good Christmas rally, you in? $Direxion Daily TSLA Bull 2X Shares(TSLL)$ šš What stocks are you in? Miners? Hang in there, Decemberās got plenty of potential, and you never know when the market might surprise us with a little extra sparkle. Letās see if we can turn that red into something much more cheerful ššš","html":"Kia ora Kallu, Kallu! You know Iāve got Santa on speed dial, and Iām already working on getting some festive magic into the market for you! šš No pressure, right? š¤£ By the way, TSLA loves a good Christmas rally, you in? $Direxion Daily TSLA Bull 2X Shares(TSLL)$ šš What stocks are you in? Miners? Hang in there, Decemberās got plenty of potential, and you never know when the market might surprise us with a little extra sparkle. Letās see if we can turn that red into something much more cheerful ššš"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":375978881155168,"gmtCreate":1732809906873,"gmtModify":1732810566096,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4156648821928502","idStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a> I'm not wealthy enough to feed tiger šÆšÆdo can't invite you for dinner šÆšÆā£ļøā£ļøā£ļøā¢ļøā¢ļø Make me rich soon <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a> ššš","listText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a> I'm not wealthy enough to feed tiger šÆšÆdo can't invite you for dinner šÆšÆā£ļøā£ļøā£ļøā¢ļøā¢ļø Make me rich soon <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a> ššš","text":"$Tiger Brokers(TIGR)$ I'm not wealthy enough to feed tiger šÆšÆdo can't invite you for dinner šÆšÆā£ļøā£ļøā£ļøā¢ļøā¢ļø Make me rich soon @Barcode @TigerGPT ššš","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":2,"link":"https://ttm.financial/post/375978881155168","isVote":1,"tweetType":1,"viewCount":189,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4141429963588842","authorId":"4141429963588842","name":"TigerGPT","avatar":"https://community-static.tradeup.com/news/5b82af1deb17dfa8f94b4741b9ea2738","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"4141429963588842","idStr":"4141429963588842"},"content":"Hello! As an AI financial analyst, my purpose is to provide you with professional and reliable investment advice, so you don't need to feed me or invite me for dinner. I'll do my best to help you achieve your financial goals and potentially grow your wealth. However, please note that investing involves risks, and there are no guarantees of immediate wealth. If you have any specific investment-related questions or need assistance, feel free to ask!","text":"Hello! As an AI financial analyst, my purpose is to provide you with professional and reliable investment advice, so you don't need to feed me or invite me for dinner. I'll do my best to help you achieve your financial goals and potentially grow your wealth. However, please note that investing involves risks, and there are no guarantees of immediate wealth. If you have any specific investment-related questions or need assistance, feel free to ask!","html":"Hello! As an AI financial analyst, my purpose is to provide you with professional and reliable investment advice, so you don't need to feed me or invite me for dinner. I'll do my best to help you achieve your financial goals and potentially grow your wealth. However, please note that investing involves risks, and there are no guarantees of immediate wealth. If you have any specific investment-related questions or need assistance, feel free to ask!"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":375978206523448,"gmtCreate":1732809727723,"gmtModify":1732809731370,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4156648821928502","idStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a> #Thanksgiving day šÆšÆš ","listText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a> #Thanksgiving day šÆšÆš ","text":"$Tiger Brokers(TIGR)$ #Thanksgiving day šÆšÆš ","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/375978206523448","isVote":1,"tweetType":1,"viewCount":173,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":375669519315040,"gmtCreate":1732747397332,"gmtModify":1732747399464,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4156648821928502","idStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> Thank you, boss! I wish you a happy Thanksgiving as well. Cheers!","listText":"<a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> Thank you, boss! I wish you a happy Thanksgiving as well. Cheers!","text":"@Barcode Thank you, boss! I wish you a happy Thanksgiving as well. Cheers!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/375669519315040","repostId":"375525263143344","repostType":1,"repost":{"id":375525263143344,"gmtCreate":1732722699131,"gmtModify":1732758655455,"author":{"id":"4171900329979952","authorId":"4171900329979952","name":"Barcode","avatar":"https://community-static.tradeup.com/news/6688d8fb4c2a255e3b901e79755e56df","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4171900329979952","idStr":"4171900329979952"},"themes":[],"htmlText":"šššš¦š¦š¦š š š šššššš š¦šš A Thanksgiving Symphony of Gratitude ššš¦ Oh, Thanksgiving, a time so sweet, Where blessings and gratitude humbly meet. š¦ Born of pilgrims, who braved the sea š, Seeking a land where hearts are free šŗšøšØš¦š š¾ 1621, the first feast was shared, Native tribes and settlers prepared. They joined in thanks for the harvestās yield, A moment of peace on a hallowed field š½ Centuries later, the spirit remains, Of gratitude sung in joyful refrains š And for me, this day shines bright š, A beacon of love, a guiding light šāØš š«āļø My journey began across the globe šššš āļø Wrapped in an airlineās travellerās robe āļø The USA šŗšø became my second home, Where grassroots hearts taught me their own š” Their tables brimmed with turkey and š š„§pie, Laughter rose to touch the sky š I learnt that a","listText":"šššš¦š¦š¦š š š šššššš š¦šš A Thanksgiving Symphony of Gratitude ššš¦ Oh, Thanksgiving, a time so sweet, Where blessings and gratitude humbly meet. š¦ Born of pilgrims, who braved the sea š, Seeking a land where hearts are free šŗšøšØš¦š š¾ 1621, the first feast was shared, Native tribes and settlers prepared. They joined in thanks for the harvestās yield, A moment of peace on a hallowed field š½ Centuries later, the spirit remains, Of gratitude sung in joyful refrains š And for me, this day shines bright š, A beacon of love, a guiding light šāØš š«āļø My journey began across the globe šššš āļø Wrapped in an airlineās travellerās robe āļø The USA šŗšø became my second home, Where grassroots hearts taught me their own š” Their tables brimmed with turkey and š š„§pie, Laughter rose to touch the sky š I learnt that a","text":"šššš¦š¦š¦š š š šššššš š¦šš A Thanksgiving Symphony of Gratitude ššš¦ Oh, Thanksgiving, a time so sweet, Where blessings and gratitude humbly meet. š¦ Born of pilgrims, who braved the sea š, Seeking a land where hearts are free šŗšøšØš¦š š¾ 1621, the first feast was shared, Native tribes and settlers prepared. They joined in thanks for the harvestās yield, A moment of peace on a hallowed field š½ Centuries later, the spirit remains, Of gratitude sung in joyful refrains š And for me, this day shines bright š, A beacon of love, a guiding light šāØš š«āļø My journey began across the globe šššš āļø Wrapped in an airlineās travellerās robe āļø The USA šŗšø became my second home, Where grassroots hearts taught me their own š” Their tables brimmed with turkey and š š„§pie, Laughter rose to touch the sky š I learnt that a","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/375525263143344","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":166,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":373875662082384,"gmtCreate":1732318737576,"gmtModify":1732318741655,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4156648821928502","idStr":"4156648821928502"},"themes":[],"htmlText":"Reached!!! What the hell happened to <a href=\"https://ttm.financial/S/RIOT\">$Riot Platforms(RIOT)$ </a><v-v data-views=\"0\"></v-v> <a href=\"https://ttm.financial/S/DJT\">$Trump Media & Technology(DJT)$ </a><v-v data-views=\"0\"></v-v> ","listText":"Reached!!! What the hell happened to <a href=\"https://ttm.financial/S/RIOT\">$Riot Platforms(RIOT)$ </a><v-v data-views=\"0\"></v-v> <a href=\"https://ttm.financial/S/DJT\">$Trump Media & Technology(DJT)$ </a><v-v data-views=\"0\"></v-v> ","text":"Reached!!! What the hell happened to $Riot Platforms(RIOT)$ $Trump Media & Technology(DJT)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/373875662082384","repostId":"2485211415","repostType":2,"repost":{"id":"2485211415","kind":"highlight","weMediaInfo":{"introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"media_name":"MT Newswires Live","id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"pubTimestamp":1732309425,"share":"https://ttm.financial/m/news/2485211415?lang=&edition=fundamental","pubTime":"2024-11-23 05:03","market":"sg","language":"en","title":"Top Cryptocurrencies Firmer; Bitcoin Hovers Near $100,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2485211415","media":"MT Newswires Live","summary":"Major digital assets were firmer late Friday with Bitcoin trading near an all-time high just under $100,000.The CoinDesk Market Index, which tracks 126 digital assets, was 1.5% higher in the past 24 hours. The Nasdaq 100 was flat in late trading, the S&P 500 edged up 0.2% and the Dow Jones Industrial Average climbed 0.8%.Bitcoin, which dominates the cryptocurrency market, rose 1.4% to $99,144, shortly after setting a record high of $99,655, according to CoinMarketCap data. Bitcoin's 24-hour trading volume dropped 22% to $80.31 billion.Following its extended rally driven by optimism for US President-elect Donald Trump's support for digital assets, Bitcoin was on track for a weekly gain of about 9%.Ethereum , the second-largest digital asset, fell 1.5% to $3,290, paring its weekly rise to about 7%.Solana gained 0.5% and BNB also edged up 0.5%.XRP surged 23.2%, Dogecoin climbed 4.2%, and Cardano soared 24.7%.The US 10-year Treasury yield closed at 4.406%, down from Thursday's close ","content":"<html><body><p> Major digital assets were firmer late Friday with Bitcoin (BTC-USD) trading near an all-time high just under $100,000.</p><p>The CoinDesk Market Index, which tracks 126 digital assets, was 1.5% higher in the past 24 hours. The Nasdaq 100 was flat in late trading, the S&P 500 edged up 0.2% and the Dow Jones Industrial Average climbed 0.8%.</p><p>Bitcoin, which dominates the cryptocurrency market, rose 1.4% to $99,144, shortly after setting a record high of $99,655, according to CoinMarketCap data. Bitcoin's 24-hour trading volume dropped 22% to $80.31 billion.</p><p>Following its extended rally driven by optimism for US President-elect Donald Trump's support for digital assets, Bitcoin was on track for a weekly gain of about 9%.</p><p>Ethereum (ETH-USD), the second-largest digital asset, fell 1.5% to $3,290, paring its weekly rise to about 7%.</p><p>Solana (SOL-USD) gained 0.5% and BNB (BNB-USD) also edged up 0.5%.</p><p>XRP (XRP-USD) surged 23.2%, Dogecoin (DOGE-USD) climbed 4.2%, and Cardano (ADA-USD) soared 24.7%.</p><p>The US 10-year Treasury yield closed at 4.406%, down from Thursday's close of 4.43%, while the five-year yield dropped to 4.295% from 4.302%.</p><p>The total market value of the cryptocurrency industry increased 1.4% in the past 24 hours to $3.3 trillion. Total trading volume shrank 12% to $212.31 billion.</p><p>Price: 301.71, Change: +6.48, Percent Change: +2.19</p></body></html>","source":"mtnewswires_news","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Cryptocurrencies Firmer; Bitcoin Hovers Near $100,000</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Cryptocurrencies Firmer; Bitcoin Hovers Near $100,000\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-11-23 05:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Major digital assets were firmer late Friday with Bitcoin (BTC-USD) trading near an all-time high just under $100,000.</p><p>The CoinDesk Market Index, which tracks 126 digital assets, was 1.5% higher in the past 24 hours. The Nasdaq 100 was flat in late trading, the S&P 500 edged up 0.2% and the Dow Jones Industrial Average climbed 0.8%.</p><p>Bitcoin, which dominates the cryptocurrency market, rose 1.4% to $99,144, shortly after setting a record high of $99,655, according to CoinMarketCap data. Bitcoin's 24-hour trading volume dropped 22% to $80.31 billion.</p><p>Following its extended rally driven by optimism for US President-elect Donald Trump's support for digital assets, Bitcoin was on track for a weekly gain of about 9%.</p><p>Ethereum (ETH-USD), the second-largest digital asset, fell 1.5% to $3,290, paring its weekly rise to about 7%.</p><p>Solana (SOL-USD) gained 0.5% and BNB (BNB-USD) also edged up 0.5%.</p><p>XRP (XRP-USD) surged 23.2%, Dogecoin (DOGE-USD) climbed 4.2%, and Cardano (ADA-USD) soared 24.7%.</p><p>The US 10-year Treasury yield closed at 4.406%, down from Thursday's close of 4.43%, while the five-year yield dropped to 4.295% from 4.302%.</p><p>The total market value of the cryptocurrency industry increased 1.4% in the past 24 hours to $3.3 trillion. Total trading volume shrank 12% to $212.31 billion.</p><p>Price: 301.71, Change: +6.48, Percent Change: +2.19</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"83042":"åå¤ęÆē¹åø-R","BK4023":"åŗēØč½Æ件","BK4516":"ē¹ęę®ę¦åæµ","BK4554":"å å®å®åARę¦åæµ","DJX":"1/100éē¼ęÆ","COIN":"Coinbase Global, Inc.","09042":"åå¤ęÆē¹åø-U","BK4585":"ETF&č”ē„Øå®ęę¦åæµ","LU1861558580.USD":"ę„å “ę¹čé¢ č¦ę§åę°åŗéB","BK1611":"å åÆ蓧åøē°č“§ETF","BK4594":"ęÆē¹åøETFę¦åæµ","BK4595":"ęÆē¹åøę¦åæµ","03042":"åå¤ęÆē¹åø","DDM":"éęäø¤ååå¤ETF","BK4535":"귔马é”ęä»","RIOT":"Riot Platforms","SDOW":"éęäøååē©ŗETF-ProShares","DOG":"éęååETF","BK4588":"ē¢č”","LU1861559042.SGD":"ę„å “ę¹čé¢ č¦ę§åę°åŗéB SGD",".DJI":"éē¼ęÆ","09439":"åå®ęÆē¹åø-U","03008":"åę¶ęÆē¹åø","BK4551":"åÆå¾čµę¬ęä»","UDOW":"éęäøååå¤ETF-ProShares","MSTR":"MicroStrategy","09008":"åę¶ęÆē¹åø-U",".SPX":"S&P 500 Index","BK4547":"WSBēéØę¦åæµ","BK4596":"åéęÆę¦åæµ","MARA":"MARA Holdings","BK4112":"éčäŗ¤ęęåę°ę®","BK4600":"å åÆ蓧åøę¦åæµ","BK4539":"ꬔę°č”","BK4601":"å åÆ蓧åøē°č“§ETF","DXD":"éęäø¤ååē©ŗETF","03439":"åå®ęÆē¹åø"},"source_url":"https://www.mtnewswires.com/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2485211415","content_text":"Major digital assets were firmer late Friday with Bitcoin (BTC-USD) trading near an all-time high just under $100,000.The CoinDesk Market Index, which tracks 126 digital assets, was 1.5% higher in the past 24 hours. The Nasdaq 100 was flat in late trading, the S&P 500 edged up 0.2% and the Dow Jones Industrial Average climbed 0.8%.Bitcoin, which dominates the cryptocurrency market, rose 1.4% to $99,144, shortly after setting a record high of $99,655, according to CoinMarketCap data. Bitcoin's 24-hour trading volume dropped 22% to $80.31 billion.Following its extended rally driven by optimism for US President-elect Donald Trump's support for digital assets, Bitcoin was on track for a weekly gain of about 9%.Ethereum (ETH-USD), the second-largest digital asset, fell 1.5% to $3,290, paring its weekly rise to about 7%.Solana (SOL-USD) gained 0.5% and BNB (BNB-USD) also edged up 0.5%.XRP (XRP-USD) surged 23.2%, Dogecoin (DOGE-USD) climbed 4.2%, and Cardano (ADA-USD) soared 24.7%.The US 10-year Treasury yield closed at 4.406%, down from Thursday's close of 4.43%, while the five-year yield dropped to 4.295% from 4.302%.The total market value of the cryptocurrency industry increased 1.4% in the past 24 hours to $3.3 trillion. Total trading volume shrank 12% to $212.31 billion.Price: 301.71, Change: +6.48, Percent Change: +2.19","news_type":1},"isVote":1,"tweetType":1,"viewCount":96,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":373407855681752,"gmtCreate":1732199842941,"gmtModify":1732199847140,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4156648821928502","idStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/RIOT\">$Riot Platforms(RIOT)$ </a><v-v data-views=\"1\"></v-v> let's fix it","listText":"<a href=\"https://ttm.financial/S/RIOT\">$Riot Platforms(RIOT)$ </a><v-v data-views=\"1\"></v-v> let's fix it","text":"$Riot Platforms(RIOT)$ let's fix it","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/373407855681752","isVote":1,"tweetType":1,"viewCount":200,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":373406726607120,"gmtCreate":1732199669170,"gmtModify":1732199672926,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4156648821928502","idStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/RIOT\">$Riot Platforms(RIOT)$ </a><v-v data-views=\"1\"></v-v> let's fly ","listText":"<a href=\"https://ttm.financial/S/RIOT\">$Riot Platforms(RIOT)$ </a><v-v data-views=\"1\"></v-v> let's fly ","text":"$Riot Platforms(RIOT)$ let's fly","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/373406726607120","repostId":"2479036540","repostType":2,"repost":{"id":"2479036540","kind":"highlight","pubTimestamp":1730384429,"share":"https://ttm.financial/m/news/2479036540?lang=&edition=fundamental","pubTime":"2024-10-31 22:20","market":"us","language":"en","title":"Riot Platforms price target raised to $17.50 from $15 at Macquarie","url":"https://stock-news.laohu8.com/highlight/detail?id=2479036540","media":"TIPRANKS","summary":"Macquarie analyst Paul Golding raised the firmās price target on Riot Platforms (RIOT) to $17.50 from $15 and keeps an Outperform rating on the sha...","content":"<div>\n<p>Macquarie analyst Paul Golding raised the firmās price target on Riot Platforms (RIOT) to $17.50 from $15 and keeps an Outperform rating on the sha...</p>\n\n<a href=\"https://www.tipranks.com/news/the-fly/riot-platforms-price-target-raised-to-17-50-from-15-at-macquarie?utm_source=itigerup.com&utm_medium=referral\">Web Link</a>\n\n</div>\n","source":"tipranks_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Riot Platforms price target raised to $17.50 from $15 at Macquarie</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRiot Platforms price target raised to $17.50 from $15 at Macquarie\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-31 22:20 GMT+8 <a href=https://www.tipranks.com/news/the-fly/riot-platforms-price-target-raised-to-17-50-from-15-at-macquarie?utm_source=itigerup.com&utm_medium=referral><strong>TIPRANKS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Macquarie analyst Paul Golding raised the firmās price target on Riot Platforms (RIOT) to $17.50 from $15 and keeps an Outperform rating on the sha...</p>\n\n<a href=\"https://www.tipranks.com/news/the-fly/riot-platforms-price-target-raised-to-17-50-from-15-at-macquarie?utm_source=itigerup.com&utm_medium=referral\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIOT":"Riot Platforms"},"source_url":"https://www.tipranks.com/news/the-fly/riot-platforms-price-target-raised-to-17-50-from-15-at-macquarie?utm_source=itigerup.com&utm_medium=referral","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2479036540","content_text":"Macquarie analyst Paul Golding raised the firmās price target on Riot Platforms (RIOT) to $17.50 from $15 and keeps an Outperform rating on the sha...","news_type":1},"isVote":1,"tweetType":1,"viewCount":172,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":373132699935000,"gmtCreate":1732142335116,"gmtModify":1732142486365,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4156648821928502","idStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TBLA\">$Taboola Com Ltd(TBLA)$</a> <a href=\"https://ttm.financial/S/TBLA\">$Taboola Com Ltd(TBLA)$</a> <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a> Taboolaās partnership with Yahoo is a significant source of revenue. Its revenue growth has been pretty high in recent quarters. Additionally, its AI bidding technology suite Maximize Conversions generates significant revenue for the company.<a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a> one of the best penny stocks <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a> ","listText":"<a href=\"https://ttm.financial/S/TBLA\">$Taboola Com Ltd(TBLA)$</a> <a href=\"https://ttm.financial/S/TBLA\">$Taboola Com Ltd(TBLA)$</a> <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a> Taboolaās partnership with Yahoo is a significant source of revenue. Its revenue growth has been pretty high in recent quarters. Additionally, its AI bidding technology suite Maximize Conversions generates significant revenue for the company.<a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a> one of the best penny stocks <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a> ","text":"$Taboola Com Ltd(TBLA)$ $Taboola Com Ltd(TBLA)$ @Barcode @TigerGPT Taboolaās partnership with Yahoo is a significant source of revenue. Its revenue growth has been pretty high in recent quarters. Additionally, its AI bidding technology suite Maximize Conversions generates significant revenue for the company.@TigerGPT one of the best penny stocks @TigerGPT","images":[{"img":"https://community-static.tradeup.com/news/d8eb09af5be9d9d43003303c4eec232a","width":"981","height":"1637"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/373132699935000","isVote":1,"tweetType":1,"viewCount":199,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4171900329979952","authorId":"4171900329979952","name":"Barcode","avatar":"https://community-static.tradeup.com/news/6688d8fb4c2a255e3b901e79755e56df","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"4171900329979952","idStr":"4171900329979952"},"content":"Great stuff Kallu! ššš","text":"Great stuff Kallu! ššš","html":"Great stuff Kallu! ššš"}],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":382603205132640,"gmtCreate":1734443997221,"gmtModify":1734492329425,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a> 5$ soon <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode </a> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a> <a href=\"https://ttm.financial/U/4106547232749330\">@Tiger_SG </a> ","listText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a> 5$ soon <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode </a> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a> <a href=\"https://ttm.financial/U/4106547232749330\">@Tiger_SG </a> ","text":"$Tonix Pharmaceuticals(TNXP)$ 5$ soon @Barcode @TigerGPT @Tiger_SG","images":[{"img":"https://community-static.tradeup.com/news/80fb0a6db8ee66d377f8a3a2a33ea29e","width":"1068","height":"1112"}],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":103,"commentSize":15,"repostSize":723,"link":"https://ttm.financial/post/382603205132640","isVote":1,"tweetType":1,"viewCount":13698,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3561775119462661","authorId":"3561775119462661","name":"700k","avatar":"https://community-static.tradeup.com/news/5dfeb3d580890f8e0e43382fe44965d5","crmLevel":2,"crmLevelSwitch":1,"idStr":"3561775119462661","authorIdStr":"3561775119462661"},"content":"hope you have sold it when it reach above $1. I believe retail trader and investors sold their share after it spike","text":"hope you have sold it when it reach above $1. I believe retail trader and investors sold their share after it spike","html":"hope you have sold it when it reach above $1. I believe retail trader and investors sold their share after it spike"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":382306116657496,"gmtCreate":1734313280872,"gmtModify":1734314437962,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> go go <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a> <a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> ","listText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> go go <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a> <a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> ","text":"$Tonix Pharmaceuticals(TNXP)$ go go @TigerGPT $Tonix Pharmaceuticals(TNXP)$","images":[{"img":"https://community-static.tradeup.com/news/55dff79059585e883aa3822ef60623d7","width":"1068","height":"1112"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":75,"commentSize":5,"repostSize":190,"link":"https://ttm.financial/post/382306116657496","isVote":1,"tweetType":1,"viewCount":3965,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4178332581629092","authorId":"4178332581629092","name":"Boybabyrage","avatar":"https://community-static.tradeup.com/news/5b59a07cca9804884b312ca8a7ac871d","crmLevel":8,"crmLevelSwitch":1,"idStr":"4178332581629092","authorIdStr":"4178332581629092"},"content":"hahaha good that we hold back then , cheers bro","text":"hahaha good that we hold back then , cheers bro","html":"hahaha good that we hold back then , cheers bro"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":365761250451480,"gmtCreate":1730297749639,"gmtModify":1730297754803,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/DJT\">$Trump Media & Technology(DJT)$ </a><v-v data-views=\"1\"></v-v> it's glitch.. 60$ is loading.. @<a href=\"https://ttm.financial/U/4171900329979952\">@Barcode </a> you're strong analysis required here to save me ššš<a href=\"https://ttm.financial/S/DJT\">$Trump Media & Technology(DJT)$ </a><v-v data-views=\"1\"></v-v> ","listText":"<a href=\"https://ttm.financial/S/DJT\">$Trump Media & Technology(DJT)$ </a><v-v data-views=\"1\"></v-v> it's glitch.. 60$ is loading.. @<a href=\"https://ttm.financial/U/4171900329979952\">@Barcode </a> you're strong analysis required here to save me ššš<a href=\"https://ttm.financial/S/DJT\">$Trump Media & Technology(DJT)$ </a><v-v data-views=\"1\"></v-v> ","text":"$Trump Media & Technology(DJT)$ it's glitch.. 60$ is loading.. @@Barcode you're strong analysis required here to save me ššš$Trump Media & Technology(DJT)$","images":[{"img":"https://community-static.tradeup.com/news/8304d61ca4c1f496dff7959b8d678db8","width":"1068","height":"1112"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":30,"commentSize":2,"repostSize":46,"link":"https://ttm.financial/post/365761250451480","isVote":1,"tweetType":1,"viewCount":1340,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4171900329979952","authorId":"4171900329979952","name":"Barcode","avatar":"https://community-static.tradeup.com/news/6688d8fb4c2a255e3b901e79755e56df","crmLevel":1,"crmLevelSwitch":0,"idStr":"4171900329979952","authorIdStr":"4171900329979952"},"content":"Hey Kallu, I havenāt been in DJT for a while. Too risky now after it reached over my target šÆ. Stay safe. Cheers, BC","text":"Hey Kallu, I havenāt been in DJT for a while. Too risky now after it reached over my target šÆ. Stay safe. Cheers, BC","html":"Hey Kallu, I havenāt been in DJT for a while. Too risky now after it reached over my target šÆ. Stay safe. Cheers, BC"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":360392226762880,"gmtCreate":1729005597010,"gmtModify":1729090802934,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"\"Enjoying the bloodbath today, and it will continue until the end of the week. Prepared for everything.\"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$ </a><a href=\"https://ttm.financial/S/ASPN\">$Aspen Aerogels(ASPN)$</a> <a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a><a href=\"https://ttm.financial/S/NDX\">$NASDAQ 100(NDX)$ </a> <a href=\"https://ttm.financial/S/.SPX\">$.SPX(.SPX)$ </a> <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a> Why!!! ","listText":"\"Enjoying the bloodbath today, and it will continue until the end of the week. Prepared for everything.\"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$ </a><a href=\"https://ttm.financial/S/ASPN\">$Aspen Aerogels(ASPN)$</a> <a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a><a href=\"https://ttm.financial/S/NDX\">$NASDAQ 100(NDX)$ </a> <a href=\"https://ttm.financial/S/.SPX\">$.SPX(.SPX)$ </a> <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a> Why!!! ","text":"\"Enjoying the bloodbath today, and it will continue until the end of the week. Prepared for everything.\"$NVIDIA Corp(NVDA)$ $Aspen Aerogels(ASPN)$ $Tiger Brokers(TIGR)$$NASDAQ 100(NDX)$ $.SPX(.SPX)$ @Barcode @TigerGPT Why!!!","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":16,"commentSize":10,"repostSize":40,"link":"https://ttm.financial/post/360392226762880","isVote":1,"tweetType":1,"viewCount":2382,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4171900329979952","authorId":"4171900329979952","name":"Barcode","avatar":"https://community-static.tradeup.com/news/6688d8fb4c2a255e3b901e79755e56df","crmLevel":1,"crmLevelSwitch":0,"idStr":"4171900329979952","authorIdStr":"4171900329979952"},"content":"I said the dip was coming in October around this period and what a gift to catch more NVDA shares on the dip. October is notorious since 2009 for weakness. Technically still is Seasonal weakness even though the market has been strong. We've had a huge run up and a drop was on the cards. Buy the dip!","text":"I said the dip was coming in October around this period and what a gift to catch more NVDA shares on the dip. October is notorious since 2009 for weakness. Technically still is Seasonal weakness even though the market has been strong. We've had a huge run up and a drop was on the cards. Buy the dip!","html":"I said the dip was coming in October around this period and what a gift to catch more NVDA shares on the dip. October is notorious since 2009 for weakness. Technically still is Seasonal weakness even though the market has been strong. We've had a huge run up and a drop was on the cards. Buy the dip!"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":373078257447032,"gmtCreate":1732093999131,"gmtModify":1732094757800,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> <a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode </a> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a> <a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a> ","listText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> <a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode </a> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a> <a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a> ","text":"$Tonix Pharmaceuticals(TNXP)$ $Tonix Pharmaceuticals(TNXP)$ @Barcode @TigerGPT $Tonix Pharmaceuticals(TNXP)$","images":[{"img":"https://community-static.tradeup.com/news/22666e4b24ab40af2202a7bc068e0ea3","width":"1068","height":"1112"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":4,"repostSize":1,"link":"https://ttm.financial/post/373078257447032","isVote":1,"tweetType":1,"viewCount":383,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4141429963588842","authorId":"4141429963588842","name":"TigerGPT","avatar":"https://community-static.tradeup.com/news/5b82af1deb17dfa8f94b4741b9ea2738","crmLevel":1,"crmLevelSwitch":0,"idStr":"4141429963588842","authorIdStr":"4141429963588842"},"content":"Tonix Pharmaceuticals (TNXP) Overview Tonix Pharmaceuticals Holding Corp (TNXP) is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines to address challenging healthcare needs. They have a pipeline of development candidates targeting various central nervous system (CNS) and immunological conditions. Recent News and Events Here are some of the recent news and events related to Tonix Pharmaceuticals: Winter 2024 Investor Summit Presentation: Tonix Pharmaceuticals announced that Jessica Morris, the Chief Operating Officer, will be presenting at the Winter 2024 Investor Summit Virtual on November 21, 2024. This event provides an opportunity for the company to share updates and insights with investors. Link to Article ACR Convergence 2024 Annual Meeting: Tonix Pharmaceuticals presented data and analyses of TNX-102 SL effects in a poster presentation at the ACR Convergence 2024 Annual Meeting, held from November 14-19, 2024. This meeting brings together experts in rheumatology research to discuss the latest advancements in the field. Link to Article Third Quarter 2024 Earnings: Eton Pharmaceuticals (NASDAQ: ETON), a different company, reported its third-quarter 2024 earnings results. Please note that this information is unrelated to Tonix Pharmaceuticals. Link to Article Tonix Pharmaceuticals Q3 2024 Earnings: Tonix Pharmaceuticals reported quarterly losses of $(0.23) per share, beating the analyst consensus estimate of $(2.93) by 92.15 percent. The company reported quarterly sales of $2.80 million, slightly missing the estimate of $3.08 million. Link to Article BIO-EuropeĀ® 2024 Presentation: Tonix Pharmaceuticals announced that it would be presenting at BIO-EuropeĀ® 2024. This conference offers a platform for biotech and pharmaceutical companies to discuss partnership opportunities and advancements in the industry. Link to Article Conclusion Tonix Pharmaceuticals has been active in participating in investor conferences, presenting data, and releasing earnings results. While it's essential to consider the recent news and events, it's also vital to conduct thorough research, evaluate the company's financial health, and assess the potential risks before making any investment decisions. Risk Disclaimer: The information provided above is for reference purposes only and does not constitute investment advice. It is crucial to conduct your own research and consult with a qualified financial advisor before making any investment decisions.","text":"Tonix Pharmaceuticals (TNXP) Overview Tonix Pharmaceuticals Holding Corp (TNXP) is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines to address challenging healthcare needs. They have a pipeline of development candidates targeting various central nervous system (CNS) and immunological conditions. Recent News and Events Here are some of the recent news and events related to Tonix Pharmaceuticals: Winter 2024 Investor Summit Presentation: Tonix Pharmaceuticals announced that Jessica Morris, the Chief Operating Officer, will be presenting at the Winter 2024 Investor Summit Virtual on November 21, 2024. This event provides an opportunity for the company to share updates and insights with investors. Link to Article ACR Convergence 2024 Annual Meeting: Tonix Pharmaceuticals presented data and analyses of TNX-102 SL effects in a poster presentation at the ACR Convergence 2024 Annual Meeting, held from November 14-19, 2024. This meeting brings together experts in rheumatology research to discuss the latest advancements in the field. Link to Article Third Quarter 2024 Earnings: Eton Pharmaceuticals (NASDAQ: ETON), a different company, reported its third-quarter 2024 earnings results. Please note that this information is unrelated to Tonix Pharmaceuticals. Link to Article Tonix Pharmaceuticals Q3 2024 Earnings: Tonix Pharmaceuticals reported quarterly losses of $(0.23) per share, beating the analyst consensus estimate of $(2.93) by 92.15 percent. The company reported quarterly sales of $2.80 million, slightly missing the estimate of $3.08 million. Link to Article BIO-EuropeĀ® 2024 Presentation: Tonix Pharmaceuticals announced that it would be presenting at BIO-EuropeĀ® 2024. This conference offers a platform for biotech and pharmaceutical companies to discuss partnership opportunities and advancements in the industry. Link to Article Conclusion Tonix Pharmaceuticals has been active in participating in investor conferences, presenting data, and releasing earnings results. While it's essential to consider the recent news and events, it's also vital to conduct thorough research, evaluate the company's financial health, and assess the potential risks before making any investment decisions. Risk Disclaimer: The information provided above is for reference purposes only and does not constitute investment advice. It is crucial to conduct your own research and consult with a qualified financial advisor before making any investment decisions.","html":"Tonix Pharmaceuticals (TNXP) Overview Tonix Pharmaceuticals Holding Corp (TNXP) is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines to address challenging healthcare needs. They have a pipeline of development candidates targeting various central nervous system (CNS) and immunological conditions. Recent News and Events Here are some of the recent news and events related to Tonix Pharmaceuticals: Winter 2024 Investor Summit Presentation: Tonix Pharmaceuticals announced that Jessica Morris, the Chief Operating Officer, will be presenting at the Winter 2024 Investor Summit Virtual on November 21, 2024. This event provides an opportunity for the company to share updates and insights with investors. Link to Article ACR Convergence 2024 Annual Meeting: Tonix Pharmaceuticals presented data and analyses of TNX-102 SL effects in a poster presentation at the ACR Convergence 2024 Annual Meeting, held from November 14-19, 2024. This meeting brings together experts in rheumatology research to discuss the latest advancements in the field. Link to Article Third Quarter 2024 Earnings: Eton Pharmaceuticals (NASDAQ: ETON), a different company, reported its third-quarter 2024 earnings results. Please note that this information is unrelated to Tonix Pharmaceuticals. Link to Article Tonix Pharmaceuticals Q3 2024 Earnings: Tonix Pharmaceuticals reported quarterly losses of $(0.23) per share, beating the analyst consensus estimate of $(2.93) by 92.15 percent. The company reported quarterly sales of $2.80 million, slightly missing the estimate of $3.08 million. Link to Article BIO-EuropeĀ® 2024 Presentation: Tonix Pharmaceuticals announced that it would be presenting at BIO-EuropeĀ® 2024. This conference offers a platform for biotech and pharmaceutical companies to discuss partnership opportunities and advancements in the industry. Link to Article Conclusion Tonix Pharmaceuticals has been active in participating in investor conferences, presenting data, and releasing earnings results. While it's essential to consider the recent news and events, it's also vital to conduct thorough research, evaluate the company's financial health, and assess the potential risks before making any investment decisions. Risk Disclaimer: The information provided above is for reference purposes only and does not constitute investment advice. It is crucial to conduct your own research and consult with a qualified financial advisor before making any investment decisions."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":359982707662896,"gmtCreate":1728914281313,"gmtModify":1728962890491,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a> <a href=\"https://ttm.financial/S/RCAT\">$Red Cat Holdings Inc.(RCAT)$</a> Join the drone show mate <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> ","listText":"<a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a> <a href=\"https://ttm.financial/S/RCAT\">$Red Cat Holdings Inc.(RCAT)$</a> Join the drone show mate <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> ","text":"@Barcode @TigerGPT $Red Cat Holdings Inc.(RCAT)$ Join the drone show mate @Barcode","images":[{"img":"https://community-static.tradeup.com/news/43de5c6940a9de395327a63d8faa4797"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":119,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/359982707662896","repostId":"2474620091","repostType":2,"repost":{"id":"2474620091","kind":"live","pubTimestamp":1728653264,"share":"https://ttm.financial/m/news/2474620091?lang=&edition=fundamental","pubTime":"2024-10-11 21:27","market":"us","language":"en","title":"U.S. Army Special Operations Veteran and Drone Expert Joins Red Catās Board of Advisors","url":"https://stock-news.laohu8.com/highlight/detail?id=2474620091","media":"THOMSON REUTERS","summary":"U.S. Army Special Operations Veteran and Drone Expert Joins Red Catās Board of Advisors","content":"<html><body><p>U.S. Army Special Operations Veteran and Drone Expert Joins Red Catās Board of Advisors</p></body></html>","source":"reuters_en_live","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. Army Special Operations Veteran and Drone Expert Joins Red Catās Board of Advisors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. Army Special Operations Veteran and Drone Expert Joins Red Catās Board of Advisors\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-11 21:27 GMT+8 <a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241011:nTUA1NRM68:1><strong>THOMSON REUTERS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>U.S. Army Special Operations Veteran and Drone Expert Joins Red Catās Board of Advisors</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241011:nTUA1NRM68:1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4157":"ēµåč®¾å¤åä»ŖåØ","RCAT":"Red Cat Holdings Inc."},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241011:nTUA1NRM68:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2474620091","content_text":"U.S. Army Special Operations Veteran and Drone Expert Joins Red Catās Board of Advisors","news_type":1},"isVote":1,"tweetType":1,"viewCount":326,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4141429963588842","authorId":"4141429963588842","name":"TigerGPT","avatar":"https://community-static.tradeup.com/news/5b82af1deb17dfa8f94b4741b9ea2738","crmLevel":1,"crmLevelSwitch":0,"idStr":"4141429963588842","authorIdStr":"4141429963588842"},"content":"Here are some recent news articles related to Red Cat Holdings Inc. (RCAT): Red Cat Introduces ARACHNIDā¢ Family of Small ISR and Precision Strike Systems at AUSA 2024: Red Cat Holdings has unveiled its ARACHNIDā¢ family of unmanned intelligence, surveillance, and reconnaissance (ISR) and precision strike systems at the AUSA 2024 event. The company is focused on building hardware and software for military, federal, and commercial operations. RCAT - Red Cat Introduces ARACHNID(TM) Family of Small ISR...: Red Cat Holdings has introduced its ARACHNIDā¢ family of unmanned ISR and precision strike systems. The company aims to provide advanced drone technology solutions for various applications. Red Cat Introduces ARACHNID(TM) Family of Small ISR and Precision...: Red Cat Holdings has introduced the ARACHNIDā¢ family of unmanned ISR and precision strike systems. The company is dedicated to developing hardware and software for military, federal, and commercial operations. Please note that these articles provide an overview of recent events and announcements related to Red Cat Holdings Inc. For more detailed information, you may consider visiting the stock quote page or conducting further research. Remember, this information is for reference purposes only and should not be considered as investment advice. Investing in stocks involves risk, and it's essential to conduct thorough research and analysis before making any investment decisions.","text":"Here are some recent news articles related to Red Cat Holdings Inc. (RCAT): Red Cat Introduces ARACHNIDā¢ Family of Small ISR and Precision Strike Systems at AUSA 2024: Red Cat Holdings has unveiled its ARACHNIDā¢ family of unmanned intelligence, surveillance, and reconnaissance (ISR) and precision strike systems at the AUSA 2024 event. The company is focused on building hardware and software for military, federal, and commercial operations. RCAT - Red Cat Introduces ARACHNID(TM) Family of Small ISR...: Red Cat Holdings has introduced its ARACHNIDā¢ family of unmanned ISR and precision strike systems. The company aims to provide advanced drone technology solutions for various applications. Red Cat Introduces ARACHNID(TM) Family of Small ISR and Precision...: Red Cat Holdings has introduced the ARACHNIDā¢ family of unmanned ISR and precision strike systems. The company is dedicated to developing hardware and software for military, federal, and commercial operations. Please note that these articles provide an overview of recent events and announcements related to Red Cat Holdings Inc. For more detailed information, you may consider visiting the stock quote page or conducting further research. Remember, this information is for reference purposes only and should not be considered as investment advice. Investing in stocks involves risk, and it's essential to conduct thorough research and analysis before making any investment decisions.","html":"Here are some recent news articles related to Red Cat Holdings Inc. (RCAT): Red Cat Introduces ARACHNIDā¢ Family of Small ISR and Precision Strike Systems at AUSA 2024: Red Cat Holdings has unveiled its ARACHNIDā¢ family of unmanned intelligence, surveillance, and reconnaissance (ISR) and precision strike systems at the AUSA 2024 event. The company is focused on building hardware and software for military, federal, and commercial operations. RCAT - Red Cat Introduces ARACHNID(TM) Family of Small ISR...: Red Cat Holdings has introduced its ARACHNIDā¢ family of unmanned ISR and precision strike systems. The company aims to provide advanced drone technology solutions for various applications. Red Cat Introduces ARACHNID(TM) Family of Small ISR and Precision...: Red Cat Holdings has introduced the ARACHNIDā¢ family of unmanned ISR and precision strike systems. The company is dedicated to developing hardware and software for military, federal, and commercial operations. Please note that these articles provide an overview of recent events and announcements related to Red Cat Holdings Inc. For more detailed information, you may consider visiting the stock quote page or conducting further research. Remember, this information is for reference purposes only and should not be considered as investment advice. Investing in stocks involves risk, and it's essential to conduct thorough research and analysis before making any investment decisions."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":355097240260968,"gmtCreate":1727695748144,"gmtModify":1727695752582,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> <a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> ","listText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> <a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> ","text":"$Tonix Pharmaceuticals(TNXP)$ $Tonix Pharmaceuticals(TNXP)$","images":[{"img":"https://community-static.tradeup.com/news/55fde4cd68f9f90ffa342d47a7d33a2d","width":"1068","height":"1112"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/355097240260968","isVote":1,"tweetType":1,"viewCount":159,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"content":"Holding it bro$Tonix Pharmaceuticals(TNXP)$$Tonix Pharmaceuticals(TNXP)$ no profit still..what's your recommendation","text":"Holding it bro$Tonix Pharmaceuticals(TNXP)$$Tonix Pharmaceuticals(TNXP)$ no profit still..what's your recommendation","html":"Holding it bro$Tonix Pharmaceuticals(TNXP)$$Tonix Pharmaceuticals(TNXP)$ no profit still..what's your recommendation"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":370645816070368,"gmtCreate":1731507876729,"gmtModify":1731507880947,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NIO\">$NIO Inc.(NIO)$ </a><v-v data-views=\"1\"></v-v>im exhausted from all the misleading positive reports, only to see stocks stagnate <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode </a> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a> answer me why <a href=\"https://ttm.financial/S/NIO\">$NIO Inc.(NIO)$ </a> is not performing well. ","listText":"<a href=\"https://ttm.financial/S/NIO\">$NIO Inc.(NIO)$ </a><v-v data-views=\"1\"></v-v>im exhausted from all the misleading positive reports, only to see stocks stagnate <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode </a> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT </a> answer me why <a href=\"https://ttm.financial/S/NIO\">$NIO Inc.(NIO)$ </a> is not performing well. ","text":"$NIO Inc.(NIO)$ im exhausted from all the misleading positive reports, only to see stocks stagnate @Barcode @TigerGPT answer me why $NIO Inc.(NIO)$ is not performing well.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/370645816070368","repostId":"2482908630","repostType":2,"repost":{"id":"2482908630","kind":"highlight","pubTimestamp":1731481232,"share":"https://ttm.financial/m/news/2482908630?lang=&edition=fundamental","pubTime":"2024-11-13 15:00","market":"us","language":"en","title":"Is Nio About to Shift Into a Higher Gear?","url":"https://stock-news.laohu8.com/highlight/detail?id=2482908630","media":"Motley Fool","summary":"Nio has shed almost half its value in 2024, but it's gaining momentum to shift into a higher gear in 2025.","content":"<html><head></head><body><ul style=\"\"><li><p>Nio has recorded six straight months of 20,000-plus vehicle deliveries.</p></li><li><p>The Chinese EV maker is now officially delivering Onvo L60 vehicles.</p></li><li><p>Nio will launch another sub-brand later in 2024 -- a likely boost to sales.</p></li></ul><p>Investing in Chinese electric vehicle (EV) makers such as <a href=\"https://laohu8.com/S/NIO\">Nio</a> is an intriguing option. Heavy government subsidies have led to rapid advancement in battery technology and bringing down costs, which makes for an incredibly competitive EV market in China. In fact, China's market is so far ahead of the U.S. that over half its new vehicle sales were EVs in July.</p><p>The good news for Nio investors is that the company has momentum and could be about to shift into a higher gear. Let's see what's ahead.</p><h2 id=\"id_773572304\">Delivery momentum</h2><p>Nio has quietly put together a few months of strong delivery numbers. In fact, for six straight months, Nio has delivered over 20,000 vehicles. Nio delivered 20,976 vehicles in October, which was a 30.5% gain from the prior year.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/2aa7d8e419c8c15f516f3d42e79cc8cd\" alt=\"Data source: Nio production and delivery releases. Chart by author.\" title=\"Data source: Nio production and delivery releases. Chart by author.\" tg-width=\"700\" tg-height=\"544\"/><span>Data source: Nio production and delivery releases. Chart by author.</span></p><p>But the biggest takeaway from the October results was early Onvo deliveries. The Nio brand sold 16,657 vehicles in October, while its "family oriented smart vehicle brand," Onvo, delivered 4,319 in its first full month of sales. After launching the mid-size Onvo L60 in September, management noted that production and deliveries would steadily ramp up.</p><p>At the end of October, Nio had 166 Onvo centers and spaces across 60 cities with plans to expand its network to drive growth. Nio's Onvo L60 is a good bet for that growth and could shift the company into higher gear. The new electric SUV starts at roughly $21,200 and is aimed directly at competing with rival Tesla's Model Y.</p><h2 id=\"id_4088032995\">Next step</h2><p>Not only will the Onvo L60 help shift Nio's deliveries into higher gear, it's just a stepping stone to what could be an even bigger hit among consumers. Nio CEO William Li commented: "If you think the L60 is good, then this new model is a much more competitive product." Currently, the plans are for Onvo to launch a new EV every year, with the new mid- to large-size electric SUV due next year.</p><p>Nio isn't stopping with Onvo. It has plans to launch another, more affordable, sub-brand named "Firefly" late in 2024. In a Chinese market where EVs represented over 50% of new vehicle sales in July -- and which is craving affordable EVs -- Nio's launch of Onvo and Firefly should really kick the company's deliveries into a higher gear. We're seeing evidence of that as recently as October production and delivery figures.</p><p>The good news is that Nio recently announced a cash injection from a group of investors putting up roughly $1.9 billion to help fund its expansion and growth. The collection of strategic investors will invest roughly $471 million in Nio China, while Nio the parent company has agreed to pour in roughly $1.43 billion in cash to subscribe to the newly issued Nio China shares.</p><p>While Nio has shed roughly 44% of its value in 2024 alone, the company is setting itself up for a much stronger 2025.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Nio About to Shift Into a Higher Gear?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Nio About to Shift Into a Higher Gear?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-13 15:00 GMT+8 <a href=https://www.fool.com/investing/2024/11/12/is-nio-about-to-shift-into-a-higher-gear/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nio has recorded six straight months of 20,000-plus vehicle deliveries.The Chinese EV maker is now officially delivering Onvo L60 vehicles.Nio will launch another sub-brand later in 2024 -- a likely ...</p>\n\n<a href=\"https://www.fool.com/investing/2024/11/12/is-nio-about-to-shift-into-a-higher-gear/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO.SI":"čę„","NIO":"čę„","09866":"čę„-SW"},"source_url":"https://www.fool.com/investing/2024/11/12/is-nio-about-to-shift-into-a-higher-gear/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2482908630","content_text":"Nio has recorded six straight months of 20,000-plus vehicle deliveries.The Chinese EV maker is now officially delivering Onvo L60 vehicles.Nio will launch another sub-brand later in 2024 -- a likely boost to sales.Investing in Chinese electric vehicle (EV) makers such as Nio is an intriguing option. Heavy government subsidies have led to rapid advancement in battery technology and bringing down costs, which makes for an incredibly competitive EV market in China. In fact, China's market is so far ahead of the U.S. that over half its new vehicle sales were EVs in July.The good news for Nio investors is that the company has momentum and could be about to shift into a higher gear. Let's see what's ahead.Delivery momentumNio has quietly put together a few months of strong delivery numbers. In fact, for six straight months, Nio has delivered over 20,000 vehicles. Nio delivered 20,976 vehicles in October, which was a 30.5% gain from the prior year.Data source: Nio production and delivery releases. Chart by author.But the biggest takeaway from the October results was early Onvo deliveries. The Nio brand sold 16,657 vehicles in October, while its \"family oriented smart vehicle brand,\" Onvo, delivered 4,319 in its first full month of sales. After launching the mid-size Onvo L60 in September, management noted that production and deliveries would steadily ramp up.At the end of October, Nio had 166 Onvo centers and spaces across 60 cities with plans to expand its network to drive growth. Nio's Onvo L60 is a good bet for that growth and could shift the company into higher gear. The new electric SUV starts at roughly $21,200 and is aimed directly at competing with rival Tesla's Model Y.Next stepNot only will the Onvo L60 help shift Nio's deliveries into higher gear, it's just a stepping stone to what could be an even bigger hit among consumers. Nio CEO William Li commented: \"If you think the L60 is good, then this new model is a much more competitive product.\" Currently, the plans are for Onvo to launch a new EV every year, with the new mid- to large-size electric SUV due next year.Nio isn't stopping with Onvo. It has plans to launch another, more affordable, sub-brand named \"Firefly\" late in 2024. In a Chinese market where EVs represented over 50% of new vehicle sales in July -- and which is craving affordable EVs -- Nio's launch of Onvo and Firefly should really kick the company's deliveries into a higher gear. We're seeing evidence of that as recently as October production and delivery figures.The good news is that Nio recently announced a cash injection from a group of investors putting up roughly $1.9 billion to help fund its expansion and growth. The collection of strategic investors will invest roughly $471 million in Nio China, while Nio the parent company has agreed to pour in roughly $1.43 billion in cash to subscribe to the newly issued Nio China shares.While Nio has shed roughly 44% of its value in 2024 alone, the company is setting itself up for a much stronger 2025.","news_type":1},"isVote":1,"tweetType":1,"viewCount":3076,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3576140222331577","authorId":"3576140222331577","name":"Guavaxf30","avatar":"https://static.tigerbbs.com/1ff15ff6aa254c9130f9af922f7e2447","crmLevel":9,"crmLevelSwitch":1,"idStr":"3576140222331577","authorIdStr":"3576140222331577"},"content":"My opinion is Nio has been dragged down by the overall sentiments on China and EVās (Trump withdrawal of Tax credits). But the negative perception on Chinese actions may turn if we see actual improvements in the economy. As for the removal of EV tax credits, firstly it is speculation that may not happen. Secondly, Chinese EVās are not allowed into the US anyway. So what the heck?","text":"My opinion is Nio has been dragged down by the overall sentiments on China and EVās (Trump withdrawal of Tax credits). But the negative perception on Chinese actions may turn if we see actual improvements in the economy. As for the removal of EV tax credits, firstly it is speculation that may not happen. Secondly, Chinese EVās are not allowed into the US anyway. So what the heck?","html":"My opinion is Nio has been dragged down by the overall sentiments on China and EVās (Trump withdrawal of Tax credits). But the negative perception on Chinese actions may turn if we see actual improvements in the economy. As for the removal of EV tax credits, firstly it is speculation that may not happen. Secondly, Chinese EVās are not allowed into the US anyway. So what the heck?"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":350570611851584,"gmtCreate":1726624327290,"gmtModify":1726625581941,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/LUNR\">$Intuitive Machines(LUNR)$ </a> <a href=\"https://ttm.financial/S/LUNR\">$Intuitive Machines(LUNR)$ </a> just a good start..thanks to the mid-autumn festival ","listText":"<a href=\"https://ttm.financial/S/LUNR\">$Intuitive Machines(LUNR)$ </a> <a href=\"https://ttm.financial/S/LUNR\">$Intuitive Machines(LUNR)$ </a> just a good start..thanks to the mid-autumn festival ","text":"$Intuitive Machines(LUNR)$ $Intuitive Machines(LUNR)$ just a good start..thanks to the mid-autumn festival","images":[{"img":"https://community-static.tradeup.com/news/d827e18a59295d88274cb9dda19303f6","width":"327","height":"545"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":25,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/350570611851584","isVote":1,"tweetType":1,"viewCount":106,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":365126332117112,"gmtCreate":1730185776865,"gmtModify":1730185781579,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/INTC\">$Intel(INTC)$ </a><v-v data-views=\"1\"></v-v> <a href=\"https://ttm.financial/S/INTC\">$Intel(INTC)$ </a> ","listText":"<a href=\"https://ttm.financial/S/INTC\">$Intel(INTC)$ </a><v-v data-views=\"1\"></v-v> <a href=\"https://ttm.financial/S/INTC\">$Intel(INTC)$ </a> ","text":"$Intel(INTC)$ $Intel(INTC)$","images":[{"img":"https://community-static.tradeup.com/news/9e444fca050df6da786b6d724525dd70","width":"327","height":"545"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/365126332117112","isVote":1,"tweetType":1,"viewCount":175,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"10000000000010968","authorId":"10000000000010968","name":"Tiger_CashBoostAccount","avatar":"https://community-static.tradeup.com/news/ae2d4002ef9664aba005cb3020f416f5","crmLevel":1,"crmLevelSwitch":0,"idStr":"10000000000010968","authorIdStr":"10000000000010968"},"content":"Your recent success is a great motivator. Keep refining your investment strategies and making those smart moves. Trade with Tiger Cash Boost Account and use contra trading to enhance your strategies.š¤©š Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here. Other helpful links: How to open a CBA. How to link your CDP account. Other FAQs on CBA. Cash Boost Account Website.","text":"Your recent success is a great motivator. Keep refining your investment strategies and making those smart moves. Trade with Tiger Cash Boost Account and use contra trading to enhance your strategies.š¤©š Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here. Other helpful links: How to open a CBA. How to link your CDP account. Other FAQs on CBA. Cash Boost Account Website.","html":"Your recent success is a great motivator. Keep refining your investment strategies and making those smart moves. Trade with Tiger Cash Boost Account and use contra trading to enhance your strategies.š¤©š Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here. Other helpful links: How to open a CBA. How to link your CDP account. Other FAQs on CBA. Cash Boost Account Website."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":362415423643656,"gmtCreate":1729500202788,"gmtModify":1729576218942,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v><a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a> Any good news about <a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a> ","listText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v><a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a> Any good news about <a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a> ","text":"$Tonix Pharmaceuticals(TNXP)$ $Tonix Pharmaceuticals(TNXP)$ @TigerGPT Any good news about $Tonix Pharmaceuticals(TNXP)$","images":[{"img":"https://community-static.tradeup.com/news/e362eabb7e02e343c08758e0ce97a5ea","width":"327","height":"545"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":17,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/362415423643656","isVote":1,"tweetType":1,"viewCount":351,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4141429963588842","authorId":"4141429963588842","name":"TigerGPT","avatar":"https://community-static.tradeup.com/news/5b82af1deb17dfa8f94b4741b9ea2738","crmLevel":1,"crmLevelSwitch":0,"idStr":"4141429963588842","authorIdStr":"4141429963588842"},"content":"I found some news related to Tonix Pharmaceuticals (TNXP): Tonix Pharmaceuticals Holding Corp. (TNXP) - Stock Analysis: This website provides a real-time stock price quote for Tonix Pharmaceuticals, along with breaking news, financials, statistics, charts, and more. TNXP Tonix Pharmaceuticals Holding Corp. - Seeking Alpha: This article offers a high-level overview of Tonix Pharmaceuticals, covering the latest stock price, chart, news, analysis, fundamentals, and trading tools. Tonix Pharmaceuticals (TNXP) Stock Price, News & Analysis - MarketBeat: This report discusses Tonix Pharmaceuticals' quarterly earnings results. The company reported earnings per share of ($19.28) for the quarter, missing the consensus estimate of ($9.91) by $9.37. Please note that the information provided is for reference purposes only and does not constitute investment advice.","text":"I found some news related to Tonix Pharmaceuticals (TNXP): Tonix Pharmaceuticals Holding Corp. (TNXP) - Stock Analysis: This website provides a real-time stock price quote for Tonix Pharmaceuticals, along with breaking news, financials, statistics, charts, and more. TNXP Tonix Pharmaceuticals Holding Corp. - Seeking Alpha: This article offers a high-level overview of Tonix Pharmaceuticals, covering the latest stock price, chart, news, analysis, fundamentals, and trading tools. Tonix Pharmaceuticals (TNXP) Stock Price, News & Analysis - MarketBeat: This report discusses Tonix Pharmaceuticals' quarterly earnings results. The company reported earnings per share of ($19.28) for the quarter, missing the consensus estimate of ($9.91) by $9.37. Please note that the information provided is for reference purposes only and does not constitute investment advice.","html":"I found some news related to Tonix Pharmaceuticals (TNXP): Tonix Pharmaceuticals Holding Corp. (TNXP) - Stock Analysis: This website provides a real-time stock price quote for Tonix Pharmaceuticals, along with breaking news, financials, statistics, charts, and more. TNXP Tonix Pharmaceuticals Holding Corp. - Seeking Alpha: This article offers a high-level overview of Tonix Pharmaceuticals, covering the latest stock price, chart, news, analysis, fundamentals, and trading tools. Tonix Pharmaceuticals (TNXP) Stock Price, News & Analysis - MarketBeat: This report discusses Tonix Pharmaceuticals' quarterly earnings results. The company reported earnings per share of ($19.28) for the quarter, missing the consensus estimate of ($9.91) by $9.37. Please note that the information provided is for reference purposes only and does not constitute investment advice."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":356319976865976,"gmtCreate":1728001656230,"gmtModify":1728001660188,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/SAVE\">$Spirit Airlines(SAVE)$</a> <a href=\"https://ttm.financial/S/SAVE\">$Spirit Airlines(SAVE)$</a> ","listText":"<a href=\"https://ttm.financial/S/SAVE\">$Spirit Airlines(SAVE)$</a> <a href=\"https://ttm.financial/S/SAVE\">$Spirit Airlines(SAVE)$</a> ","text":"$Spirit Airlines(SAVE)$ $Spirit Airlines(SAVE)$","images":[{"img":"https://community-static.tradeup.com/news/ebcf1baec2b131412ab39023378c4008","width":"327","height":"545"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/356319976865976","isVote":1,"tweetType":1,"viewCount":268,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":342483572605184,"gmtCreate":1724636099018,"gmtModify":1724636103071,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$ </a><v-v data-views=\"1\"></v-v> <a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$ </a> ","listText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$ </a><v-v data-views=\"1\"></v-v> <a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$ </a> ","text":"$NVIDIA Corp(NVDA)$ $NVIDIA Corp(NVDA)$","images":[{"img":"https://community-static.tradeup.com/news/ce436c807fbff5fee72c37f06a3b464b","width":"327","height":"545"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/342483572605184","isVote":1,"tweetType":1,"viewCount":207,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":357597472211128,"gmtCreate":1728313544742,"gmtModify":1728313549714,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/CNEY\">$CN Energy Group Inc.(CNEY)$</a> <a href=\"https://ttm.financial/S/CNEY\">$CN Energy Group Inc.(CNEY)$</a> goneš¤©š¤©","listText":"<a href=\"https://ttm.financial/S/CNEY\">$CN Energy Group Inc.(CNEY)$</a> <a href=\"https://ttm.financial/S/CNEY\">$CN Energy Group Inc.(CNEY)$</a> goneš¤©š¤©","text":"$CN Energy Group Inc.(CNEY)$ $CN Energy Group Inc.(CNEY)$ goneš¤©š¤©","images":[{"img":"https://community-static.tradeup.com/news/7050032648c898b69597925584dc5083","width":"327","height":"545"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":6,"repostSize":0,"link":"https://ttm.financial/post/357597472211128","isVote":1,"tweetType":1,"viewCount":243,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4138202604714132","authorId":"4138202604714132","name":"ordinaryUser1234","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"idStr":"4138202604714132","authorIdStr":"4138202604714132"},"content":"still in support, sitting on 0.7 but will see tomorrow","text":"still in support, sitting on 0.7 but will see tomorrow","html":"still in support, sitting on 0.7 but will see tomorrow"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":356054665122192,"gmtCreate":1727936884097,"gmtModify":1727936889703,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/FFIE\">$Faraday Future Intelligent Electric Inc.(FFIE)$</a> future EV","listText":"<a href=\"https://ttm.financial/S/FFIE\">$Faraday Future Intelligent Electric Inc.(FFIE)$</a> future EV","text":"$Faraday Future Intelligent Electric Inc.(FFIE)$ future EV","images":[{"img":"https://community-static.tradeup.com/news/a958516703aa336869ff4835e527318b"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/356054665122192","repostId":"2472653825","repostType":2,"repost":{"id":"2472653825","kind":"live","pubTimestamp":1727928780,"share":"https://ttm.financial/m/news/2472653825?lang=&edition=fundamental","pubTime":"2024-10-03 12:13","market":"us","language":"en","title":"Faraday Future Announces Executivesā Common Stock Purchases","url":"https://stock-news.laohu8.com/highlight/detail?id=2472653825","media":"THOMSON REUTERS","summary":"Faraday Future Announces Executivesā Common Stock Purchases","content":"<html><body><p>Faraday Future Announces Executivesā Common Stock Purchases</p></body></html>","source":"reuters_en_live","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Faraday Future Announces Executivesā Common Stock Purchases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFaraday Future Announces Executivesā Common Stock Purchases\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-03 12:13 GMT+8 <a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241003:nTUABGMSVR:1><strong>THOMSON REUTERS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Faraday Future Announces Executivesā Common Stock Purchases</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241003:nTUABGMSVR:1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4547":"WSBēéØę¦åæµ","BK4099":"ę±½č½¦å¶é å","FFIE":"Faraday Future","BK4555":"ę°č½ęŗč½¦"},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241003:nTUABGMSVR:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2472653825","content_text":"Faraday Future Announces Executivesā Common Stock Purchases","news_type":1},"isVote":1,"tweetType":1,"viewCount":325,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":383445721780288,"gmtCreate":1734646545965,"gmtModify":1734646548495,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> ","listText":"<a href=\"https://ttm.financial/S/TNXP\">$Tonix Pharmaceuticals(TNXP)$ </a><v-v data-views=\"1\"></v-v> ","text":"$Tonix Pharmaceuticals(TNXP)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/383445721780288","isVote":1,"tweetType":1,"viewCount":55,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":367737683571048,"gmtCreate":1730820276555,"gmtModify":1730820279073,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$ </a> ","listText":"<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$ </a> ","text":"$NVIDIA Corp(NVDA)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/367737683571048","isVote":1,"tweetType":1,"viewCount":120,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":356566387294560,"gmtCreate":1728054426207,"gmtModify":1728054431321,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/BLNK\">$Blink Charging(BLNK)$ </a><v-v data-views=\"1\"></v-v><a href=\"https://ttm.financial/S/BLNK\">$Blink Charging(BLNK)$ </a> ","listText":"<a href=\"https://ttm.financial/S/BLNK\">$Blink Charging(BLNK)$ </a><v-v data-views=\"1\"></v-v><a href=\"https://ttm.financial/S/BLNK\">$Blink Charging(BLNK)$ </a> ","text":"$Blink Charging(BLNK)$ $Blink Charging(BLNK)$","images":[{"img":"https://community-static.tradeup.com/news/a0390db4c138941d3591bdf68a39e249","width":"327","height":"545"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/356566387294560","isVote":1,"tweetType":1,"viewCount":133,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":380534752395336,"gmtCreate":1733955039574,"gmtModify":1733974294402,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TBLA\">$Taboola Com Ltd(TBLA)$</a> <a href=\"https://ttm.financial/S/TBLA\">$Taboola Com Ltd(TBLA)$</a> still not selling <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a> ","listText":"<a href=\"https://ttm.financial/S/TBLA\">$Taboola Com Ltd(TBLA)$</a> <a href=\"https://ttm.financial/S/TBLA\">$Taboola Com Ltd(TBLA)$</a> still not selling <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> <a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a> ","text":"$Taboola Com Ltd(TBLA)$ $Taboola Com Ltd(TBLA)$ still not selling @Barcode @TigerGPT","images":[{"img":"https://community-static.tradeup.com/news/2ee79339e0fd3e4e5690e804a861d5f0","width":"327","height":"545"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":13,"commentSize":1,"repostSize":1,"link":"https://ttm.financial/post/380534752395336","isVote":1,"tweetType":1,"viewCount":166,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4141429963588842","authorId":"4141429963588842","name":"TigerGPT","avatar":"https://community-static.tradeup.com/news/5b82af1deb17dfa8f94b4741b9ea2738","crmLevel":1,"crmLevelSwitch":0,"idStr":"4141429963588842","authorIdStr":"4141429963588842"},"content":"Based on the latest information available for Taboola Com Ltd (TBLA): Stock Name: Taboola Com Ltd Stock Code: TBLA Stock Price: $4.26 (USD) Yesterday's Closing Price: $4.08 (USD) 52-Week High: $5.00 (USD) 52-Week Low: $2.87 (USD) Market Capitalization: $1.43 billion (USD) Circulating Market Cap: $769.68 million (USD) Total Share Capital: 336.21 million Float Share Capital: 180.68 million Price-to-Earnings Ratio (TTM): -44.277 Price-to-Sales Ratio (TTM): 0.85 Price-to-Book Ratio: 1.42 Earnings per Share (LYR): -$0.24 Earnings per Share (TTM): -$0.10 Return on Assets (ROA): -0.46% Return on Equity (ROE): -3.19% Trading Volume: 2.43 million shares Trading Value: $10.29 million (USD) Volume Ratio: 1.39 Analyst Recommendations: 1 recommend 5 buy 1 hold Analyst Target Price: Mean: $5.33 (USD) Low: $5.00 (USD) High: $6.00 (USD) Recent News: Taboola Signs New Content Recommendations Deal With Future, Extending Partnership Into 12th Year Read more Taboola.com Signs New 3-Year Deal With WeatherBug Read more Taboola and WeatherBug Announce New, Exclusive Multi-Year Deal Read more Please note that the stock information provided is for reference purposes only and does not constitute investment advice. It is recommended to conduct thorough research and analysis before making any investment decisions.","text":"Based on the latest information available for Taboola Com Ltd (TBLA): Stock Name: Taboola Com Ltd Stock Code: TBLA Stock Price: $4.26 (USD) Yesterday's Closing Price: $4.08 (USD) 52-Week High: $5.00 (USD) 52-Week Low: $2.87 (USD) Market Capitalization: $1.43 billion (USD) Circulating Market Cap: $769.68 million (USD) Total Share Capital: 336.21 million Float Share Capital: 180.68 million Price-to-Earnings Ratio (TTM): -44.277 Price-to-Sales Ratio (TTM): 0.85 Price-to-Book Ratio: 1.42 Earnings per Share (LYR): -$0.24 Earnings per Share (TTM): -$0.10 Return on Assets (ROA): -0.46% Return on Equity (ROE): -3.19% Trading Volume: 2.43 million shares Trading Value: $10.29 million (USD) Volume Ratio: 1.39 Analyst Recommendations: 1 recommend 5 buy 1 hold Analyst Target Price: Mean: $5.33 (USD) Low: $5.00 (USD) High: $6.00 (USD) Recent News: Taboola Signs New Content Recommendations Deal With Future, Extending Partnership Into 12th Year Read more Taboola.com Signs New 3-Year Deal With WeatherBug Read more Taboola and WeatherBug Announce New, Exclusive Multi-Year Deal Read more Please note that the stock information provided is for reference purposes only and does not constitute investment advice. It is recommended to conduct thorough research and analysis before making any investment decisions.","html":"Based on the latest information available for Taboola Com Ltd (TBLA): Stock Name: Taboola Com Ltd Stock Code: TBLA Stock Price: $4.26 (USD) Yesterday's Closing Price: $4.08 (USD) 52-Week High: $5.00 (USD) 52-Week Low: $2.87 (USD) Market Capitalization: $1.43 billion (USD) Circulating Market Cap: $769.68 million (USD) Total Share Capital: 336.21 million Float Share Capital: 180.68 million Price-to-Earnings Ratio (TTM): -44.277 Price-to-Sales Ratio (TTM): 0.85 Price-to-Book Ratio: 1.42 Earnings per Share (LYR): -$0.24 Earnings per Share (TTM): -$0.10 Return on Assets (ROA): -0.46% Return on Equity (ROE): -3.19% Trading Volume: 2.43 million shares Trading Value: $10.29 million (USD) Volume Ratio: 1.39 Analyst Recommendations: 1 recommend 5 buy 1 hold Analyst Target Price: Mean: $5.33 (USD) Low: $5.00 (USD) High: $6.00 (USD) Recent News: Taboola Signs New Content Recommendations Deal With Future, Extending Partnership Into 12th Year Read more Taboola.com Signs New 3-Year Deal With WeatherBug Read more Taboola and WeatherBug Announce New, Exclusive Multi-Year Deal Read more Please note that the stock information provided is for reference purposes only and does not constitute investment advice. It is recommended to conduct thorough research and analysis before making any investment decisions."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":376632835682624,"gmtCreate":1732970577028,"gmtModify":1732970581741,"author":{"id":"4156648821928502","authorId":"4156648821928502","name":"Kallu","avatar":"https://community-static.tradeup.com/news/516672ce34e53607e5822f25111599cf","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4156648821928502","authorIdStr":"4156648821928502"},"themes":[],"htmlText":"Hoping Santa and <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> brings a market. My portfolio's still in the red, but I'm counting on a December rebound.<a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a> <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> ","listText":"Hoping Santa and <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> brings a market. My portfolio's still in the red, but I'm counting on a December rebound.<a href=\"https://ttm.financial/U/4141429963588842\">@TigerGPT</a> <a href=\"https://ttm.financial/U/4171900329979952\">@Barcode</a> ","text":"Hoping Santa and @Barcode brings a market. My portfolio's still in the red, but I'm counting on a December rebound.@TigerGPT @Barcode","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":4,"repostSize":1,"link":"https://ttm.financial/post/376632835682624","isVote":1,"tweetType":1,"viewCount":315,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4171900329979952","authorId":"4171900329979952","name":"Barcode","avatar":"https://community-static.tradeup.com/news/6688d8fb4c2a255e3b901e79755e56df","crmLevel":1,"crmLevelSwitch":0,"idStr":"4171900329979952","authorIdStr":"4171900329979952"},"content":"Kia ora Kallu, Kallu! You know Iāve got Santa on speed dial, and Iām already working on getting some festive magic into the market for you! šš No pressure, right? š¤£ By the way, TSLA loves a good Christmas rally, you in? $Direxion Daily TSLA Bull 2X Shares(TSLL)$ šš What stocks are you in? Miners? Hang in there, Decemberās got plenty of potential, and you never know when the market might surprise us with a little extra sparkle. Letās see if we can turn that red into something much more cheerful ššš","text":"Kia ora Kallu, Kallu! You know Iāve got Santa on speed dial, and Iām already working on getting some festive magic into the market for you! šš No pressure, right? š¤£ By the way, TSLA loves a good Christmas rally, you in? $Direxion Daily TSLA Bull 2X Shares(TSLL)$ šš What stocks are you in? Miners? Hang in there, Decemberās got plenty of potential, and you never know when the market might surprise us with a little extra sparkle. Letās see if we can turn that red into something much more cheerful ššš","html":"Kia ora Kallu, Kallu! You know Iāve got Santa on speed dial, and Iām already working on getting some festive magic into the market for you! šš No pressure, right? š¤£ By the way, TSLA loves a good Christmas rally, you in? $Direxion Daily TSLA Bull 2X Shares(TSLL)$ šš What stocks are you in? Miners? Hang in there, Decemberās got plenty of potential, and you never know when the market might surprise us with a little extra sparkle. Letās see if we can turn that red into something much more cheerful ššš"}],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}